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CHAPTER I: INTRODUCTION AND BACKGROUND 
Ovarian cancer 
Ovarian cancer is the fifth leading cause of cancer death in women, the leading cause of 
death from gynecologic malignancies, and the second most commonly diagnosed gynecologic 
malignancy [1].  It is projected that in 2013, approximately 22,240 women will receive a new 
diagnosis of ovarian cancer and 14,230 will die from ovarian cancer [2].  Ovarian cancer can be 
divided into three broad subgroups, epithelial, stromal, and germ cell tumors, each with different 
etiologies and clinical behavior, with epithelial ovarian cancer (EOC) amounting to more than 
85% of all cases [3].  Sex cord stromal tumors of the ovary account for about 5% to 8% while 
neoplasms of germ cell origin account for about 3% of ovarian malignancies [4].  In general, 
ovarian cancers originate in the epithelium of inclusion cysts, which are derived from the surface 
epithelium [5].  While most epithelial tumors, including a subset of low grade adenocarcinomas 
of the ovary (endometrioid and mucinous) follow the adenoma-carcinoma sequence, high grade 
serous ovarian carcinoma (HGSOC) often exhibits a unique pattern of progression in which no 
tumor can be found on the surface of the ovary during the early stages [5].  In contrast, in most 
HGSOCs, as the tumor grows, the intact ovarian outer surface is disrupted and the cancer 
extends to the pelvic region [6].  Early stage ovarian cancer is typically asymptomatic which 
results in most cases presenting with late stage (III or IV) disease [7].  Unfortunately, the five-
year survival rate of patients with advanced disease is approximately 30%, with even lower 
survival among African-American women [7,8].  Risk factors include family history, BRCA1/2 
mutations, nulliparity, obesity, advanced age, race, and pregnancy after the age of 35 [7].  On the 
other hand, a decreased risk of ovarian cancer occurs with the use of oral contraceptives, 
pregnancy and childbirth, hysterectomy and oophorectomy [7].  Currently used screening and 
diagnostic methods for ovarian cancer include pelvic examination and CA-125 antigen as a 
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tumor marker and transvaginal ultrasound (TVU), although the sensitivity and specificity of 
these methods are insufficient for screening the general population [9].  
The deficiency in diagnostic tools, including the lack of serum markers for the detection 
of early neoplastic changes in epithelial cells has led to this disease being diagnosed most often 
in later stages resulting in poor prognosis.  Recommended treatment of ovarian cancer includes a 
combination of surgery and a chemotherapeutics, platinums and taxanes, yet relapse is common 
due to the acquisition of chemotherapy resistance resulting in disease recurrence in 70% of 
patients who underwent treatment within 18 months [8,10].  While large-scale gene expression 
analyses have been done to identify differentially expressed genes in ovarian carcinoma for 
diagnosis of early-stage ovarian cancer, as well as the use of such markers as targets for 
improved therapy and treatment, to date these have not yielded reproducible prognostic 
indicators for identification and clinical outcomes [11-19].  
Sources of oxidative stress 
Oxidative stress has been implicated in the pathogenesis of several malignancies 
including bladder, brain, breast, cervical, gastric, liver, lung, melanoma, multiple myeloma, 
leukemia, lymphoma, oral, ovarian, pancreatic, prostate, and sarcoma cancers [20,21].  Moreover, 
there is evidence that ovarian cancer patients also have decreased levels of circulating 
antioxidants [21].  The imbalance between the production and elimination of free radicals and 
reactive metabolites leads to a state of oxidative stress and subsequent damage of important 
biomolecules and cells, with potential impact on the whole organism [22].  Reactive oxygen 
species (ROS) include superoxide (O2●−), hydroxyl radical (˙OH●), hydrogen peroxide (H2O2), 
peroxynitrite (ONOO−) and hypohalous acids, and are free radical molecules that are highly 
destructive to cellular functions [23,24].  Various enzyme systems produce ROS, including the 
mitochondrial electron transport chain, cytochrome P450, lipoxygenase, cyclooxygenase, the 
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nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase complex, xanthine oxidase 
(XO), and peroxisomes (Figure 1) [25,26].   
Mitochondrial O2 metabolism is the dominant source of O2●− that results from incomplete 
coupling of electrons and H+ with O2 in the electron transport chain.  Under normal conditions, 
ROS are maintained within narrow parameters by scavenging systems, as would be expected 
where those enzymes are involved in cell signaling, while ROS formed after exposure to 
oxidative stress can activate signaling molecules [25-33].  The redox balance is maintained by 
various enzyme systems that neutralize toxic reactive oxygen and nitrogen species.  Superoxide 
dismutases (SOD) catalyze the conversion of O2●– to hydrogen peroxide (H2O2), which then can 
be converted to water by catalase (CAT) or glutathione peroxidase (GPX) coupled with 
 
 
Figure 1: Summary of the mechanisms that will be examined in this study.  
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glutathione reductase (GSR) (Figure 1) [34].  Other important scavengers include thioredoxin 
coupled with thioredoxin reductase, and glutaredoxin, which utilizes glutathione (GSH) as a 
substrate (Figure 1).  Additionally, glutathione S-transferases (GST) are involved in 
detoxification of varieties of environmental carcinogens and xenobiotics by catalyzing their 
conjugation to GSH, and subsequent removal from the cell [35].  Glutathione plays a central role 
in maintaining redox homeostasis, and the GSH-to-oxidized-GSH ratio provides an estimate of 
cellular redox buffering capacity [25,36].  
Cancer cells are known to be under intrinsic oxidative stress resulting in increased DNA 
mutations or DNA damage, genome instability, and cellular proliferation [22,34,37-39].  The 
persistent generation of cellular ROS is a consequence of many factors including exposure to 
carcinogens, infection, inflammation, environmental toxicants, nutrients, and mitochondrial 
respiration [40-43].  Nitration of tyrosine residues to 3-nitrotyrosine, a hallmark of inflammation 
as well as a footprint of many types of oxidative injury, may play a role in the pathogenesis of 
human ovarian cancers [44].  Specifically, an increased expression of pro-oxidant enzymes such 
as inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO), NAD(P)H oxidase, as well 
as an increase in NO as indicated by increased nitrate/nitrite has been shown in epithelial ovarian 
cancer (EOC) tissues and cells [45-47].  Epithelial ovarian cancer (EOC) cells have been shown 
to have significantly increased levels of nitric oxide (NO), which correlated with increased 
expression in ]iNOS [46].  Also, EOC cells manifested lower apoptosis, which was markedly 
induced by inhibiting iNOS by L-NAME, indicating a strong link between apoptosis and 
NO/iNOS pathways in these cells [46].  Myeloperoxidase utilizes NO, produced by iNOS, as a 
one-electron substrate generating NO+, a labile nitrosating species that is rapidly hydrolyzed 
forming nitrite (NO2-) as an end product [48-51].  The ability of MPO to generate NO+, from NO, 
led us to believe that not only does MPO play a role in S-nitrosylation of caspase-3, thus 
5 
 
inhibiting caspases-3 activity, which is indicative of lower apoptosis in EOC cells, but also 
highlights a possible cross-talk between iNOS and MPO [45].  Myeloperoxidase, an abundant 
hemoprotein previously believed to be present solely in neutrophils and monocytes, plays an 
essential role in immune surveillance and host defense mechanisms, can contribute to 3-
nitrotyrosine formations in vivo and directly modulate inflammatory responses via regulation of 
NO bioavailability during inflammation [44,52].  
Several pro-oxidants have been demonstrated to be increased in cancer. Specifically, 
increased iNOS expression is elevated in breast, colorectal,  brain, esophagus, lung, prostate, 
bladder, ovarian and pancreatic cancers [53,54].  NAD(P)H oxidase family members have also 
been shown to increase in association with ROS production and tumorigenicity in several 
cancers including colon, prostate, melanoma, breast and ovarian [55].  Myeloperoxidase has been 
reported to be elevated in gynecologic malignancies but has been suggested to be a result of 
infiltrating neutrophils and macrophages [56].  High levels of HIF-1 expression are also observed 
in many human cancers, and are correlated with tumorigenesis [55].  On the other hand, elevated 
serum GST-pi levels were observed in patients with various gastrointestinal malignancies as well 
as in breast, esophageal, pancreatic, hepatocellular, and biliary tract cancers [57,58].  Several 
other antioxidant enzymes have been indicated to be differentially expressed in cancer.  
Glutathione peroxidase expression is reduced in prostate, bladder and in estrogen-negative breast 
cancer cell lines, activity is reduced in cancerous kidney tissues but increased in breast cancer 
tissues [57,59,60].  Glutathione reductase levels have also been reported to be elevated in lung 
cancer although differentially expressed in breast and kidney cancerous tissues [61-63].  
Additionally, CAT was decreased in breast, bladder, and lung cancer while increased in brain 
cancer [64-67]. Superoxide dismutase is highly expressed in lung, colorectal, gastric and breast 
cancer, while decreased SOD activity and expression have also been reported in colorectal 
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carcinomas and pancreatic cancer cells [28,66-70]. Collectively, this differential expression of 
antioxidants demonstrates the unique and complex microenvironment of cancer. 
Another major source of O2●− in several cell types is NAD(P)H oxidase, which has been 
reported to be elevated in ovarian cancer [47,71-76].  NAD(P)H oxidase consists of seven 
isoforms: five NAD(P)H oxidases (NOX), NOXs1–5, and two NOX homologues, DUOX1 and 
DUOX2.  NAD(P)H oxidases are differentially activated by different binding molecules, 
including p22phox, p40phox, p47phox/NOXO1, p67phox/NOXA1 and Rac [77].  Activation 
mechanisms and tissue distribution of the different members of the family are markedly different.  
Activation of NAD(P)H oxidase involves the translocation of regulatory elements from the 
cytoplasm to combine with catalytic subunits in the membrane [78].  Increased NAD(P)H 
oxidase activity contributes to a large number or pathologies, such as cardiovascular diseases and 
neurodegeneration [71].  It has been reported that mutations in specific regions of NAD(P)H 
oxidase subunits contribute to the enhancement of the enzyme activity with subsequent increase 
in O2●− production, contributing to enhanced levels of oxidative stress [79,80].  Specifically, an 
increase in NAD(P)H oxidase activity has been associated with a specific single nucleotide 
polymorphism (SNP) in the CYBA gene (rs4673), encoding the p22phox subunit of NAD(P)H 
oxidase, resulting in a CAC/TAC replacement at position 242 located on chromosome 16q24, 
leading to a nonconservative substitution of histidine-72 with a tyrosine [81].  This SNP is also 
associated with an increased risk for other diseases where oxidative stress plays a critical role in 
their pathophysiology, including cardiovascular disease, asthma, and diabetic nephropathy [81-
83].  
There is compelling evidence to support the role of oxidative stress in the pathogenesis of 
ovarian cancer, yet the mechanisms responsible for the dissemination of EOC are not fully 
understood.  The objective of this work is to identify mechanisms of oxidative stress and their 
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role in the pathogenesis of ovarian cancer.  The central hypothesis of this study is that ovarian 
cancer is controlled by mechanisms that emanate from an altered redox balance.  
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CHAPTER II: GENERAL METHODS 
(This chapter contains previously published material. See Appendix [45,47]) 
Cell Lines, Media, and Cell Culture Conditions 
Human epithelial ovarian cancer (EOC) cell lines, MDAH-2774 (CRL-10303™) and 
SKOV-3 (HTB-77™), were obtained from American Type Culture Collection (ATCC, Manassas, 
VA).  The MDAH-2774 cell line was developed from cells in the ascitic fluid from a patient with 
adenocarcenoma in 1972 and forms tumors in nude mice [84].  SKOV-3 cells were developed 
from ascitic fluid of a 64-year-old Caucasian female.  Cell lines were cultured in 75cm2 cell 
culture flasks (Corning Incorporated, Corning, NY) with McCoy’s 5A medium (Invitrogen, 
Carlsbad, CA) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin and 10% 
heat-inactivated fetal bovine serum (FBS) at 37 °C in 5% CO2.  Culture medium was replaced 
every two days.  
The human primary ovarian surface epithelial (HOSEpiC) cells were obtained from 
ScienCell Research Laboratories (Carlsbad, CA).  Cells were isolated from human ovarian tissue 
and were cultured with Ovarian Epithelial Cell Medium (OEpiCM, ScienCell), consisting of 500 
ml of basal medium, 5 ml of Ovarian Epithelial Cell Growth Supplement (OEpiCGS, SicenCell) 
and 5 ml of penicillin/streptomycin solution (P/S, ScienCell).  These cells were cryopreserved at 
either primary or passage one and have been utilized in other studies [85-87].  Cells were 
cultured according to the manufacturer’s instructions. 
RNA Isolation 
Total RNA was extracted from cells using an RNeasy Mini Kit (QIAGEN, Valencia, CA) 
according to the protocol provided by the manufacturer. 
Reverse Transcription 
A 20 μL cDNA reaction volume utilizing 1 μg RNA was prepared using the QuantiTect 
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Reverse Transcription Kit (Qiagen), as described by the manufacturer's protocol. 
Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Real-time RT-PCR was performed with a QuantiTect SYBR Green RT-PCR kit 
(QIAGEN) and a Cepheid 1.2f Detection System (Cepheid, Sunnyvale, CA).  Each 25-µL 
reaction included 12.5 μL of 2 x QuantiTect SYBR Green RT-PCR master mix, cDNA template, 
and 0.2 μM each of target-specific primer were selected with the aid of the software program, 
Beacon Designer (Premier Biosoft, Palo Alto, CA).  Human oligonucleotide primers that amplify 
variable portions of the protein coding regions are listed in Table 1. MPO and iNOS were 
normalized utilizing the housekeeping gene, β-actin while all other genes listed in Table 1 were 
quantified using a specific standard for each gene which allows for absolute quantification of that 
gene in number of copies, which can then be expressed per μg of RNA.  These standards have 
known concentrations and lengths that allowed for construction of a standard curve using a 
tenfold dilution series.  To evaluate the validity of using β-actin as an internal standard and 
changes in the amounts of β-actin, mRNA was tested as an external standard.  Subsequently, the 
normalized values of the mRNA were divided by those in controls.  
 
Table 1. Real-time RT-PCR primer sequences and cycling conditions.
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The conditions for the three-step polymerase chain reaction protocol were as follows: an 
initial cycle at as described in Table 1, followed by 35 cycles of denaturation at 95°C for 15s, 
annealing as described in Table 1, and extension at 72°C for 30s.  Finally, a melting curve 
analysis was performed to demonstrate the specificity of the PCR product as a single peak.  A 
control, which contained all the reaction components except for the template, was included in all 
experiments.  
Immunofluorescent Staining for iNOS and MPO 
Cells in Culture:  EOC cells were grown on a Lab-Tek Chamber slide (Sigma Chemicals, 
St. Louis, MO) overnight at 37 °C.  The cells were washed briefly with phosphate buffer saline 
solution (PBS) and fixed with 3% paraformaldehyde for 30 minutes followed by washing with 
PBS three times. Cells were blocked with 1% bovine serum albumin (BSA).  
Tissue sections: Normal ovarian and ovarian cancer tissue sections were heated to 65 C 
for 2 hours followed by deparaffinization in 2 changes of xylenes (Sigma, St. Louis, MO), 5 
minutes each.  Tissues were rehydrated in 2 changes of 100% ethanol for 3 minutes each 
followed by 2 changes of 95% ethanol for 1 minute each and 2 changes of 80% ethanol for 1 
minute each.  Slides were rinsed in distilled water and incubated in 3% H2O2 for 20 minutes at 
room temperature to block endogenous peroxidase activity followed by washing with 0.05% 
Tween 20-PBS 3 times, 5 minutes each.  Slides underwent antigen retrieval by being incubated 
in sodium citrate buffer at 95 C for 20 minutes and then were allowed to come to room 
temperature followed by washing with 0.05% Tween 20-PBS 3 times, 5 minutes each. Tissues 
sections were blocked with 10% BSA. 
Slides and chambers were incubated with the FITC-conjugated iNOS and Texas Red-
conjugated MPO antibodies (mouse anti-iNOS monoclonal antibody; BD Bioscience, rabbit anti-
myeloperoxidase polyclonal antibody; Abcam, Cambridge, MA) diluted at 1:100 ratio for 1 hour 
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at room temperature.  The cover slips were mounted on the slide with a drop of mounting 
medium containing DAPI (Invitrogen), sealed with nail polish and stored in dark at 4 °C.  Slides 
were examined with the Axiovert 25 inverted microscope (Zeiss, Thornwood, NY) using DAPI 
(blue), Texas red (red) and FITC (green), fluorescent filters with excitation and emission 
wavelengths of 365 and 445, 470 and 525, and 596 and 613 nm respectively. Images were taken 
using the Axiovision software (Zeiss) and a microscope-mounted camera. 
Immunohistochemical Staining for iNOS, MPO and NAD(P)H Oxidase 
Tissue sections: For iNOS and MPO, benign ovarian tissues specimens (n=20), obtained 
from cases who underwent salpingo-oophorectomy for benign uterine pathology, and invasive 
epithelial ovarian cancer cases (n=20) retrieved from archival materials from the Detroit Medical 
Center/ Karmanos Cancer Center pathology department were utilized in this study.  Case 
distribution by FIGO stage was as follows: 10 were stage I, and 10 were advanced stage disease 
(II-IV) at diagnosis.  Dr. Rouba Ali-Fehmi in the Wayne State University Pathology Department, 
Detroit, MI, reviewed H&E stained slides from each case for validation/confirmation of 
diagnosis and histology.  The histological diagnoses were as follows: 10 high grade serous 
carcinomas; 5 low grade serous carcinomas, 4 grade 1 endometrioid and one grade 1 mucinous 
carcinomas.  The mean age of the 20 patients was 68 (range 38 to 89 years).  
For NAD(P)H oxidase, twenty benign ovarian tissues specimens, obtained from patients 
who underwent total abdominal hysterectomy-bilateral salpingo-oophorectomy for leiomyomas, 
and 20 invasive EOC cases (two sections per case) were retrieved from archival materials from 
the Detroit Medical Center/Karmanos Cancer Center pathology department (Institutional review 
board number 072206MP2E).  Histological diagnoses were as follows: 10 high grade and five 
low grade serous carcinomas, four grade 1 endometrioid and one grade 1 mucinous carcinomas.  
The mean age of the 20 patients was 56 (range 35-70).  
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After deparaffinizing and hydrating with phosphate-buffered saline (PBS, pH 7.4), 
sections were pretreated with 3% H2O2 for 10 minutes to remove endogenous peroxidases 
followed by incubation with goat serum for 10 minutes.  Primary antibodies for MPO (Dako, 
Denmark, A0398) and iNOS (Santa Cruz, Santa Cruz, CA, sc7271) dilution (1:100) or a primary 
antibody for NAD(P)H oxidase (HPA015475, Sigma Aldrich) dilution (1:20) was applied to 
each section followed by washing and incubation with the biotinylated secondary antibody for 10 
minutes at room temperature.  Detection was performed with AEC and counterstaining was done 
with Mayer’s hematoxylin followed by mounting.  
The expression of MPO, iNOS, or NAD(P)H oxidase was assessed based on the presence 
of cytoplasmic staining.  A gynecologic pathologist reviewed all slides, benign (2-5 slides) and 
malignant (5-15 slides).  The most positive area in every tumor or benign cases was evaluated 
and only the percentage was evaluated because most of the cases had the same intensity.  The 
scoring was assigned based on the percentage of positive epithelial cells: a zero score assigned 
for cases with no cytoplasmic staining in any cells; score 1 with <5% of cell staining positive; 
score 2 with 6-30% and score 3 with >30% of cells staining positive.  For statistical analysis, 
cases with score 0 or 1 were considered as being negative and cases with score 2 or 3 as positive. 
Measurement of Protein Concentration 
Total protein concentration of cell lysates was measured with the Pierce BCA Protein 
Assay Kit (Thermo Scientific, Rockford, Illinois) per the manufacturer’s protocol. Cell lysates 
were prepared utilizing cell lysis buffer (Cell Signaling Technology, Danvers, MA) 
supplemented with Protease Arrest (G-Biosciences, St. Louis, MO).  
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CHAPTER III: CHARACTERIZATION OF THE OXIDATIVE STRESS PROFILE IN 
EPITHELIAL OVARIAN CANCER 
(This chapter contains previously published material. See Appendix [45,47]) 
Approach 
The objective of this chapter is to characterize the oxidative stress profile in EOC.  
Expression of iNOS, MPO and NAD(P)H oxidase, was determined using immunohistochemistry 
in EOC cell lines, SKOV-3 and MDAH-2774, normal human ovarian surface epithelial cell line, 
HOSEpiC, as well as in EOC tissues and their normal counterparts.  
The activity levels for CAT, SOD, GPX and GSR were measured in, MDAH-2774, 
SKOV-3, and HOSEpiC cells utilizing ELISA assays.  Cells were seeded (2.5 x 106) in 150 mm 
dishes and allowed to rest for 24 hrs followed by media replacement and cell collection 24 hrs 
later.  Cells were collected for RNA and protein extraction as well as media collected for 
measurement of nitrate/nitrite and total GSH levels.  Following RNA extraction, reverse 
transcription of cDNA was performed which was then utilized in real-time RT-PCR for 
determination of CAT, GSR, GPX1, and GST-p1 mRNA levels.   
Data were analyzed with unpaired Student’s t-tests comparing EOC to HOSEpiC cells.  A 
of p<0.05 was considered statistically significant for all analyses. 
Introduction 
The imbalance between the production and elimination of free radicals and reactive 
metabolites leads to a state of oxidative stress and subsequent damage of important biomolecules 
and cells, with potential impact on the whole organism [22].  Oxidative stress has been 
implicated in the pathogenesis of several malignancies, including ovarian cancer [20,21].  
Moreover, there is evidence that ovarian cancer patients also have decreased levels of circulating 
antioxidants such as vitamins C and E, in comparison to healthy controls [21].  Although there 
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are many players involved in the maintenance of the redox balance, we will focus on the 
following for this study.  
Epithelial ovarian cancer cells have been reported to have significantly increased levels 
of NO, which correlated with increased expression of iNOS [46].  Additionally, MPO can utilize 
NO, produced by iNOS, as a one-electron substrate generating NO+, a labile nitrosating species 
that is rapidly hydrolyzed forming nitrite (NO2-) as an end product [48-51].  The ability of MPO 
to generate NO+ led us to believe that MPO may play a role in S-nitrosylation of caspase-3, 
subsequently lowering the activity of caspase-3, ultimately reducing apoptosis in EOC cells.  
In addition to the ROS produced by the mitochondria, nicotinamide adenine dinucleotide 
phosphate (NAD(P)H)-oxidase, a flavoenzyme family member, generates a significant amount of 
endogenous ROS through the reduction of O2 to O2●–, H2O2, and other ROS [71,75,88,89].  It has 
been reported that the NAD(P)H oxidase NOX1 subunit was positively expressed in several 
cancers, including ovarian cancer tissues [90]. 
Superoxide dismutase is a major O2●– scavenger that converts O2●– to H2O2, which is 
further eliminated by both CAT and peroxidases [91,92].  Human extracellular Cu/Zn SOD 
(SOD3), is a unique SOD family member found in the extracellular matrix of tissues and is 
ideally situated to prevent cell and tissue damage, initiated by extracellularily produced ROS 
[93].  The loss of endogenous SOD3 activity can exacerbate oxidative stress and pathologic 
damage as it is a critical endogenous antioxidant enzyme involved in carcinogenesis, cancer 
proliferation and metastasis [94].  Catalase as well as GPX is involved in elimination of H2O2. 
Glutathione peroxidases detoxify peroxides with GSH acting as an electron donor in the 
reduction reaction, producing the oxidized form, GSSG, which then can be reduced by GSR, 
reforming GSH [95].  Reduced GSH is considered to be one of the most important scavengers of 
ROS, and its ratio with GSSG may be used as a marker of oxidative stress [95].  Moreover, GSR 
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is constitutively active and can be induced by oxidative stress and thus free GSH typically exists 
in the reduced form [95].  
Therefore, the goal of this chapter is to examine select pro-oxidants and antioxidants in 
order to establish an oxidative stress profile of EOC, which will contribute to delineating the 
underlying mechanisms of ovarian cancer. 
Methods 
Cell culture of EOC cell lines, MDAH-2774 and SKOV-3, and normal ovarian surface 
epithelial cells, HOSEpiC, are described in General Methods.  For SOD, CAT, GSR, GSH, and 
GPX assays, cells (2.5 x 106) were seeded in a 150 mm dish and allowed to rest for 24 hrs 
followed by media replacement and cell collection 24 hrs later.  Media was collected for 
nitrate/nitrite and total GSH measurements.  Immunohistochemistry for MPO, iNOS, and 
NAD(P)H oxidase is also described in General Methods.  
Measurement of Nitrate/Nitrite 
The nitrate/nitrite colorimetric assay (Cayman Chemical, Ann Arbor, MI) was used to 
measure the levels of stable NO by-products, nitrate (NO2−) and nitrite (NO3−), as an indication 
of NO production.  Due to the fact that the proportion of NO2− and NO3− is variable and cannot 
be predicted with certainty, the sum of both NO by-products is a more accurate indicator of NO 
production.  The assay was performed utilizing cell culture media (60 μl) according to the 
manufacturer’s protocol.  Absorbance was detected at 540 nm and a standard curve for nitrite 
was utilized to determine total NO2− and NO3−. 
Measurement of CAT Activity 
The Catalase Assay Kit (Cayman Chemical) utilizes the peroxidatic function of CAT for 
determination of enzyme activity and is based on the reaction of the enzyme with methanol in the 
presence of an optimal concentration of H2O2.  The assay was performed according to the 
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manufacturer’s protocol using 2 μg total protein.  A description of protein extraction and 
concentration determination is in General Methods.  Formaldehyde produced is measured 
spectrophotometrically with Purpald as the chromogen, which is detected at 540 nm. 
Measurement of SOD Activity 
The Superoxide Dismutase Assay Kit (Cayman Chemical) detects SOD activity by 
measuring the dismutation of O2●− generated by xanthine oxidase (XO) and hypoxanthine.  The 
standard curve generated using this enzyme provides a means to accurately quantify the activity 
of all three types of SOD (Cu/Zn-, Mn-, and Fe-SOD).  The assay was performed according to 
the manufacturer’s protocol using 0.25 μg total protein.  A description of protein extraction and 
concentration determination is in General Methods.  Total SOD was detected at 460 nm.  One 
unit of SOD is defined as the amount of enzyme needed to exhibit 50% dismutation of O2●−.   
Measurement of GSR Activity 
The Glutathione Reductase Assay Kit (Cayman Chemical) measures GSR activity by 
determining the rate of NAD(P)H oxidation which s accompanied by a decrease in absorbance at 
340 nm.  The assay was performed according to the manufacturer’s protocol using 7 μg total 
protein.  A description of protein extraction and concentration determination is in General 
Methods.  Absorbance was read once a minute for 8 minutes and slope was utilized to calculate 
GPX activity.  Since GSR is present at rate limiting concentrations, the rate of decrease in the 
absorbance at 340 nm is directly proportional to the GSR activity in the sample.  
Measurement of GPX Activity 
The Glutathione Peroxidase Assay Kit (Cayman Chemical) measures GPX activity 
indirectly by a coupled reaction with GSR [96].  Oxidized glutathione (GSSG), produced from 
the reduction of an organic hydroperoxide by GPX, is recycled to its reduced state by GSR and 
NADPH.  The oxidation of NADPH to NADP+ is accompanied by a decrease in absorbance at 
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340 nm.  The assay was performed according to the manufacturer’s protocol using 10-15 μg total 
protein, and was normalized per μg protein.  A description of protein extraction and 
concentration determination is in General Methods.  Absorbance was read once a minute for 8 
minutes and slope was utilized to calculate GPX activity.  The rate of decrease in the absorbance 
340 is directly proportional to the GPX activity in the sample [97]. 
Statistical Analysis 
An unpaired Student’s t-test was utilized to analyze real-time RT-PCR data comparing 
EOC to HOSEpiC cells.  A of p<0.05 was considered statistically significant for all analyses. 
Results 
MPO expression in EOC cells and tissues 
Normal ovarian and EOC tissues were dually stained with antibodies targeting iNOS 
(green) and MPO (red).  There is an increase in both iNOS and MPO fluorescence staining in 
ovarian cancer tissues as compared to normal ovarian tissues (Figure 2A).  Co-localization of 
iNOS and MPO is indicated by yellow fluorescence (Figure 2A).  Additionally, iNOS and MPO 
expression was upregulated in 70% and 65% of ovarian cancer tissue sections tested by 
immunohistochemistry, respectively (Figure 2B).  There was no detectable expression for either 
MPO or iNOS in any of the normal ovarian epithelial tissue.  The immunoreactivity that was 
observed in normal ovarian tissue sections was localized to blood vessels.  
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Co-localization of MPO and iNOS to the same cells in EOC cells. 
The EOC cell lines, SKOV-3 and MDAH2774, were dually stained with antibodies 
targeting iNOS (green) and MPO (red).  Immunoreactivity showed co-localization of iNOS and 
MPO (yellow) in both ovarian cancer cell lines (Figure 3).  
 
 
		
Figure 3 Co-localization of MPO and iNOS to the same cells in EOC cells. MPO and 
iNOS staining in MDAH-2774 and SKOV-3 EOC cells. Cells were dually stained with 
antibody against MPO (red), iNOS (green), and nuclei (blue) (100 x). Co-localization of 
MPO and iNOS is shown in yellow. Experiments were performed in triplicate.	
	
Figure 2 Immnunohistochemical staining of iNOS and MPO in normal and EOC tissues. 
A and B) Normal ovarian epithelium showed no staining for either iNOS or MPO. B) Strong 
cytoplasmic staining for iNOS and MPO is shown in a case of high grade serous carcinoma. A) 
Co-localization of iNOS and MPO was observed in ovarian cancer. Representative images of 
experiment performed in triplicate.	
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EOC tissues expressed higher levels of NAD(P)H oxidase 
NAD(P)H oxidase expression was upregulated in 65% of EOC tissue sections, tested by 
immunohistochemistry as compared to 20% detectable expression for NAD(P)H oxidase in 
normal ovarian epithelial tissue (surface epithelial inclusion cysts) (Figure 4). 
 
EOC cells have an increase in nitrate/nitrite levels as compared to normal ovarian surface 
epithelial cells 
Nitrate/nitrite levels significantly increased in MDAH-2774 (13.2 + 0.5 μM, p<0.002) 
and in SKOV-3 (8.2 + 0.0 μM, p<0.002) EOC cells as compared to HOSEpiC (3.9 + 0.2 μM) 
cells (Figure 5). 
		
Figure 4: Immunohistochemical staining of NAD(P)H oxidase in normal ovarian and 
EOC tissue sections. Normal ovarian and EOC tissue sections were stained with a primary 
antibody for NAD(P)H oxidase, followed by biotinylated secondary antibody. Detection was 
performed with AEC and counterstaining was done with Mayer’s hematoxylin followed by 
mounting and imaging (20x). The expression of NAD(P)H oxidase was assessed based on the 
presence of cytoplasmic staining.	
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EOC cells have an increase in CAT levels as compared to normal ovarian surface epithelial cells 
There was a significant increase in CAT mRNA levels in MDAH-2774 (17.4 + 0.1 pg/μg 
RNA, p<0.007) and SKOV-3 (20.6 + 3.8 pg/μg RNA, p<0.02) EOC cells as compared to 
HOSEpiC (9.45 + 1.6 pg/μg RNA), (Figure 6A).  Similarly, there was an increase in CAT 
activity in MDAH-2774 (10.3 + 0.06 nmol/min/ml, p<0.04) and SKOV-3 (10.1 + 0.01 
nmol/min/ml, p<0.04) EOC cells as compared to HOSEpiC (7.5 + 0.73 nmol/min/ml) cells 
(Figure 6B). 
 
	
Figure 5: Nitrate/nitrite levels in EOC as compared to HOSEpiC cells. The Griess assay 
was performed in 24-hour media collected from normal ovarian surface epithelial (HOSEpiC) 
and EOC cells. *p<0.002 as compared to HOSEpiC cells. Error bars represent standard 
deviation of the mean.	
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EOC cells have an increase in SOD activity levels as compared to normal ovarian surface 
epithelial cells 
There was an increase in SOD activity levels in MDAH-2774 (to 11.1 + 0.1 U/ml, 
p<0.0005) and in SKOV-3 (to 10.4 + 0.9 U/ml, p<0.04), respectively, as compared to HOSEpiC 
 
Figure 6: CAT mRNA and activity levels in EOC as compared to HOSEpiC cells. A) Real-
time RT-PCR was utilized to measure CAT mRNA levels in RNA isolated from EOC cell lines 
MDAH-2774 and SKOV-3 as well as HOSEpiC cells. B) Catalase activity was detected in 
protein obtained from EOC cell lines MDAH-2774 and SKOV-3 as well as HOSEpiC cells. 
*p<0.007, **p<0.02, and ***p<0.04 as compared to HOSEpiC cells. Error bars represent 
standard deviation of the mean.	
 
Figure 7:  SOD activity levels in EOC as compared to HOSEpiC cells. SOD activity was 
detected in protein obtained from EOC cell lines MDAH-2774 and SKOV-3 as well as 
HOSEpiC cells. *p<0.005 and **p<0.04 as compared to HOSEpiC cells.  Error bars 
represent standard deviation of the mean.	
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(8.6 + 0.2 U/ml) cells (Figure 7).  
EOC cells have an increase in GSR mRNA levels and activity as compared to normal ovarian 
surface epithelial cells 
There was an increase in GSR mRNA levels in MDAH-2774 (to 27.7 + 1.2 pg/μg RNA, 
p<0.008) and SKOV-3 (to 30.1 + 0.6 pg/μg RNA, p<0.008), as compared to HOSEpiC (16.0 + 
0.8 pg/μg RNA (Figure 8A).  Similarly, there was an increase in GSR activity in MDAH-2774 
(to 8.5 + 0.07 nmol/min/ml, p<0.001) and SKOV-3 (to 10.6 + 0.1 nmol/min/ml, p<0.001) as 
compared to HOSEpiC (2.8 + 0.04 nmol/min/ml) (Figure 8B). 
 
EOC cells have a decrease in GPX1 levels and activity as compared to normal ovarian surface 
epithelial cells 
There was a decrease in GPX1 mRNA levels in MDAH-2774 (to 0.75 + 0.2 pg/μg RNA, 
p<0.002) and SKOV-3 (to 0.63 + 0.08 pg/μg RNA, p<0.001), respectively, as compared to 
 
 
Figure 8: GSR mRNA and activity levels in EOC as compared to HOSEpiC cells. A) 
Real-time RT-PCR was utilized to measure GSR mRNA levels in RNA isolated from EOC 
cell lines MDAH-2774 and SKOV-3 as well as HOSEpiC cells. B) GSR activity was 
detected in protein obtained from EOC cell lines MDAH-2774 and SKOV-3 as well as 
HOSEpiC cells. *p<0.008 and **p<0.001 as compared to HOSEpiC cells.  Error bars 
represent standard deviation of the mean.	
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HOSEpiC (5.50 + 0.7 pg/μg RNA) (Figure 9A).  Likewise, there was a decrease in GPX1 
activity in MDAH-2774 (to 180.8 + 4.5 nmol/min/ml/μg protein, p<0.002) and SKOV-3 (to 
203.5 + 32.1 nmol/min/ml/μg protein, p<0.002), respectively, as compared to HOSEpiC (3378.5 
+ 241.3 nmol/min/ml/μg protein) (Figure 9B).  
 
EOC cells have an increase in GSTp1 mRNA levels as compared to normal ovarian surface 
epithelial cells 
There was an increase in GSTp1 mRNA levels in MDAH-2774 (to 61.9 + 2.3 pg/μg 
RNA, p<0.004) and in SKOV-3 (to 73.0 + 1.1 pg/μg RNA, p<0.002), respectively, as compared 
to HOSEpiC (21.1 + 2.3 pg/μg RNA) (Figure 10). 
Figure 9: GPX mRNA and activity levels in EOC as compared to HOSEpiC cells. A) 
Real-time RT-PCR was utilized to measure GPX1 mRNA levels in RNA isolated from EOC 
cell lines MDAH-2774 and SKOV-3 as well as HOSEpiC cells. B) GPX activity was 
detected in protein obtained from EOC cell lines MDAH-2774 and SKOV-3 as well as 
HOSEpiC cells. *p<0.002 and **p<0.001 as compared to HOSEpiC cells.  Error bars 
represent standard deviation of the mean.	
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Discussion 
Our results clearly indicate that EOC manifests a severe pro-oxidant state, which 
ultimately may be responsible for the persistence and maintenance of the oncogenic phenotype.  
Indeed we have shown that there is an increase in key pro-oxidant enzymes iNOS, MPO, and 
NAD(P)H oxidase, an increase in nitrate/nitrite, as well as an increase in key antioxidant 
enzymes CAT, SOD, GSR, and GST-p1 in ovarian cancer (Figure 11).  We also found the 
antioxidant enzyme GPX to be decreased in ovarian cancer (Figure 11). 
 
Figure 10: GSTp1 mRNA levels in EOC as compared to HOSEpiC cells. Real-time RT-
PCR was utilized to measure GST-p1 mRNA levels in RNA isolated from EOC cell lines 
MDAH-2774 and SKOV-3 as well as HOSEpiC cells. *p<0.004 and **p<0.002 as compared 
to HOSEpiC cells.  Error bars represent standard deviation of the mean.	
 
Figure 11:  Summary of oxidant and antioxidant markers in epithelial ovarian cancer 
as compared to normal ovarian tissues and normal ovarian surface epithelial cells. 
MPO, iNOS, and NAD(P)H oxidase were found to be elevated in ovarian cancer tissues as 
compared to normal ovarian tissues.  GSR, GST-p1, SOD, and CAT were elevated, while 
GPX1 was lower, in normal ovarian surface epithelial cells as compared to epithelial ovarian 
cancer cells. 
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Inducible nitric oxide synthase was previously found to be elevated in ovarian cancer 
tissues and cells [46,98].  Here, we observed an increase in NO2−/NO3− levels in MDAH-2774 
and SKOV-3 EOC cells as compared to HOSEpiC cells, which is representative of increased NO 
production from iNOS.  Nitric oxide plays an important role in cellular regulatory mechanisms, 
such as vasodilatation, inhibition of platelet aggregation, and modification of proteins [99-101].  
Nitric oxide exists in different redox states: NO•, NO+, and NO- [48]. Furthermore, O2•- reacts 
with NO to produce ONOO− [102].  It is well known that high concentrations of NO are 
proapoptotic and cytotoxic for different cells [103,104].  In contrast, low concentrations of NO 
have been shown to be protective against apoptosis [105-107].  In addition to the known cGMP-
dependent effects, NO modifies proteins containing a cysteine residue via S-nitrosylation [101].  
S-nitrosylation is a post-translational modification involving the attachment of NO to cysteine 
residues or transition metals [108].  Important S-nitrosylation targets are the caspase proteins and 
have been linked to a decrease in apoptosis. 
Myeloperoxidase was expressed in ovarian cancer tissues with little or no expression in 
normal ovarian tissues.  In addition, we observed MPO not only to be present but also to be co-
localized with iNOS expression in both SKOV-3 and MDAH-2774 EOC cell lines.  The 
presence of MPO in ovarian cancer cells is significant as MPO is believed to be present only in 
azurophilic granules of polymorphonuclear neutrophils and macrophages, and is released into the 
extracellular fluid in response to inflammation.  Therefore, the presence of MPO in EOC cells 
supports the fact that MPO is indeed present in the actual tissues of EOC and not a result of 
infiltrating immune cells.  The role of MPO in carcinogenesis has been implicated in both the 
activation of procarcinogens to genotoxic intermediates and the potentiation of xenobiotic 
carcinogenicity [109,110].  The co-localization of MPO and iNOS has also been demonstrated 
by immunohistochemical studies in cytokine-treated human neutrophils and primary granules of 
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activated leukocytes [111].  Furthermore, plasma levels and tissue expression of MPO in 
gynecologic malignancies, including ovarian cancer, were previously evaluated and it was found 
that gynecologic cancer patients had higher MPO as compared to control subjects [56].  
Our immunohistochemical results also showed that NAD(P)H oxidase is over-expressed 
in EOC tissues as compared to normal ovarian tissues.  Further support for this increase in ROS 
is demonstrated by a cross-talk between mitochondria and the O2●– generating NAD(P)H oxidase 
in ovarian tumors [90].  The mitochondria controls NAD(P)H oxidase redox signaling, therefore 
loss of this control contributes to tumorigenesis [90].  Another study found not only an increase 
in the NOX4 subunit of NAD(P)H oxidase, but that high levels of ROS production was a result 
of upregulated NOX4 in ovarian cancer cells as compared to immortalized ovarian surface 
epithelial cells [112].  
Glutathione reductase is part of the GSH antioxidant system and catalyzes the reduction 
of GSSG to GSH in the presence of NADPH, maintaining the high GSH/GSSG ratio in the cell 
[61]. Glutathione, an important antioxidant, is involved in regulating mutagenic mechanisms, 
DNA synthesis, growth, and multidrug and radiation resistance, especially in cancer [113,114].  
Due to it’s antioxidant capacity, elevated GSH levels increase resistance to oxidative stress and 
has been observed in many types of cancer [115]. Another study examined GSH levels in tissues 
and found an increase in GSH in ovarian cancer as compared to benign and normal ovarian 
tissues [116].  Glutathione is synthesized from its constituent amino acids, glycine, cysteine and 
glutamic acid by the sequential action of γ-glutamylcysteine synthetase (γ-GCS) and GSH 
synthetase, with γ-GCS being rate limiting and can also be regenerated from it’s oxidized from, 
GSSG, by GSR [117].  Synthesis of GSH occurs in the cytoplasm and GSH is imported into the 
mitochondria where it is involved in the elimination of oxidants including H2O2, HO, the 
cytotoxic Fenton reaction product, and the cytotoxic dinitrogen dioxide (N2O3) and ONOO−, 
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both which are products formed by the reaction of NO with O2 and O2−, respectively [117].  In 
this study, GSR mRNA and activity levels were found to be elevated in EOC cells as compared 
to HOSEpiC cells. Inhibition of GSR has been shown to cause both reduction of intracellular 
GSH and accumulation of GSSG resulting in increased cellular oxidative stress [118].  GSH 
depletion in mitochondria has also been associated with dysfunction and loss of cell viability in 
response to oxidative events [113].  
Another important protection against oxidative stress are the glutathione S-transferases 
(GST) which are involved in detoxification of varieties of environmental carcinogens by 
catalyzing their conjugation to GSH, and subsequent removal from the cell [35].  There are three 
main classes, alpha, mu and pi, which are ubiquitous throughout the tissues in the body with the 
pi class being most predominant in human tumors [119].  The expression of GST-pi has even 
been shown to be elevated in ovarian cancer as compared to normal ovarian tissue as well as 
being associated with resistance to chemotherapeutic drugs in ovarian cancer [119-121].  It was 
found that indeed, pi class (GST-p1) mRNA expression was elevated in EOC cells as compared 
to normal human epithelial ovarian cells.  This is significant, as GST-p1 is believed to play an 
important protective role in tumor cell pathogenesis and survival and may play a role in the 
development of ovarian cancer. 
One of the principal antioxidant enzymes for the elimination of H2O2 is GPX, which has a 
great affinity for H2O2 than CAT and thus competes with CAT for H2O2 as a substrate, resulting 
in the production of GSSG [122].  The distribution of GPX in the body and within the cells 
depends on the isoform, with the most prevalent form being GPX1, a cytosolic enzyme located 
in most tissues [123].  In this study, we found a significant decrease in both GPX1 mRNA and 
GPX activity levels in EOC as compared to HOSEpiC cells.  The GSH redox cycle is a major 
source of protection against mild oxidative stress, whereas CAT becomes increasingly important 
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in protection against severe oxidative stress [122].  
Interestingly, CAT mRNA and activity levels were elevated in EOC cells as compared to 
HOSEpiC cells.  The conversion of O2●– to H2O2 is catalyzed by SOD, and is then converted to 
H2O by CAT [34].  A recent study has demonstrated that inhibition of SOD, and subsequent 
accumulation of O2−, resulted in an increase in CAT protein levels in EOC cells as compared to 
normal ovarian epithelial cells [34].  We also found an increase in SOD activity in EOC cells as 
compared to HOSEpiC cells.  An increase in SOD activity suggests an increase in production of 
H2O2, which would in turn upregulate enzymes that eliminate excess H2O2, such as CAT.  
Additionally, elevated rates of H2O2 generation have been detected in several human cancer cell 
lines, including the ovarian cancer cell line SKOV-3, again supporting the idea that SOD would 
be upregulated to eliminate excessive H2O2 [73]. 
Collectively, this study has demonstrated that there are elevated pro-oxidants iNOS, 
MPO, and NAD(P)H oxidase as well as elevated levels of antioxidants CAT, GSR, and GST-p1, 
and decreased levels of GPX, all which suggests ovarian cancer favors a pro-oxidant state.  
These key enzymes represent potential targets for future therapeutic interventions for ovarian 
cancer. 
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CHAPTER IV: MODULATION OF REDOX SIGNALING PROMOTES APOPTOSIS IN 
EPITHELIAL OVARIAN CANCER CELLS 
(This chapter contains previously published material. See Appendix [45,47]) 
Approach 
A distinct oxidative stress profile was described in Chapter III.  In this Chapter, we 
sought to modulate key pro-oxidant enzymes that were upregulated in ovarian cancer, iNOS, 
MPO, and NAD(P)H oxidase, as compared to normal ovarian tissues and determine the effects 
on other key markers of oxidative stress and apoptosis.  
We also observed iNOS and MPO to be co-localized in the same EOC cell, thus, to 
investigate this relationship we silenced iNOS or MPO utilizing specific siRNA for iNOS or 
MPO in EOC cell lines, MDAH-2774 and SKOV-3. Cells (2 X 106) seeded in 60 mm x 15mm 
cell culture dishes and incubated with siRNA to silence either iNOS or MPO for 24 hours.  
Media was collected for measurement of nitrate/nitrite, and indicator of NO production from 
iNOS, levels following siRNA silencing of iNOS or MPO. Cells were collected for RNA and 
protein extraction.  Following RNA extraction, reverse transcription of cDNA was performed 
which was then utilized in real-time RT-PCR for determination of iNOS and MPO mRNA levels 
following silencing of iNOS or MPO.  Moreover, S-nitrosylation of caspase-3, a key control of 
caspase-3 activity, was determined utilizing immunoprecipitation/western blot following 
silencing of iNOS or MPO. 
Since NAD(P)H oxidase was found to be elevated in ovarian cancer tissues, we sought to 
modulated NAD(P)H oxidase through its inhibition with diphenyleneiodonium in cells (5 × 106) 
seeded in 100 cm2 culture dishes and treated for 24 hours.  Cells were collected for RNA and 
protein extraction.  Following RNA extraction, reverse transcription of cDNA was performed 
which was then utilized in real-time RT-PCR for determination of the NAD(P)H oxidase subunit 
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p22phox, HIF-1α, and SOD3 mRNA levels. Expression of the p22phox subunit of NAD(P)H 
oxidase was evaluated to confirm inhibition NAD(P)H oxidase.  Both HIF-1α and SOD3 protein 
levels were determined utilizing ELISA and immunoprecipitation/western blot, respectively.  
Additionally, caspase-3 activity and TUNEL staining, indicators of apoptosis, were determined 
for each experiment.   
For the siRNA study, data were analyzed using SPSS 15.0 for Windows.  A mixed model 
repeated measures ANOVA was used with treatment as the within factor and cell type as the 
between factor.  Paired comparisons with a Bonferroni correction were used to compare pairs of 
treatments. Significant interactions between treatment and cell type were analyzed with 
independent sample t-tests by cell type on each treatment.  
For the inhibition of NAD(P)H oxidase study, data were analyzed using SPSS 19.0 for 
Windows.  Additionally, data were analyzed using one-way ANOVA (analysis of variance) with 
Student Neuman-Kuels post-hoc comparisons.  P<0.05 was considered statistically significant 
for all analyses. 
Introduction 
In Chapter III we determined that indeed ovarian cancer exhibit a distinct oxidative stress 
profile favoring a pro-oxidant state.  We observed an overexpression of iNOS, MPO, and 
NAD(P)H oxidase in ovarian cancer tissues as compared to controls.  Additionally, iNOS and 
MPO were found to be co-localized in the same EOC cell, suggesting the existence of a cross-
talk relationship.  Therefore, we sought to further investigate the role of these key pro-oxidant 
enzymes following their modulation and the subsequent effect on additional key markers of 
oxidative stress as well as apoptosis.  
Malignant cells are resistant to apoptosis through a mechanism that may involve 
alterations in their redox balance.  Epithelial ovarian cancer cells have been shown to have 
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significantly increased levels of NO, which correlated with increased expression in iNOS [46].  
Also, EOC cells manifested lower apoptosis, which was markedly induced by inhibiting iNOS 
by L-NAME, indicating a strong link between apoptosis and NO/iNOS pathways in these cells 
[46].  Myeloperoxidase utilizes NO, produced by iNOS, as a one-electron substrate generating 
NO+, a labile nitrosating species that is rapidly hydrolyzed forming nitrite NO2− as an end 
product [48-51].  The ability of MPO to generate NO+, from NO, led us to believe that not only 
does MPO play a role in S-nitrosylation of caspase-3 in EOC cells, but also highlights a possible 
cross-talk between iNOS and MPO.  
Caspase-3 is known to play a critical role in controlling apoptosis, by participating in a 
cascade that is triggered in response to proapoptotic signals and culminates in cleavage of a set 
of proteins, resulting in disassembly of the cell [107,124-126].  Caspase-3 was found to be S-
nitrosylated on the catalytic-site cysteine in unstimulated human lymphocyte cell lines and 
denitrosylated upon activation of the Fas apoptotic pathway [127].  Decreased caspase-3 S-
nitrosylation was associated with an increase in intracellular caspase activity.  Caspase-3 S-
nitrosylation/denitrosylation is known to serve as an on/off switch regulating caspase activity 
during apoptosis in endothelial cells, lymphocytes and trophoblasts [128-131].  The mechanisms 
underlying S-nitrosothiol (SNO) formation in vivo are not well understood.  
Cancer cells are also known to be under intrinsic oxidative stress and manifest 
significantly increased levels of ROS, and thus express higher levels of SOD, which has been 
reported to stabilize the HIF-1α protein, enabling HIF-1α to dimerize, forming an active 
transcription factor [73,132-134].  Since rapidly growing tumors become hypoxic, questions are 
raised as to what promotes an increase in SOD, and why HIF-1α is stabilized and not degraded, 
with the increase in ROS under the hypoxic environment in cancer cells [135,136].  Restoration 
of the ROS balance in cancer cells may provide a potential therapeutic intervention to selectively 
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eliminate cancer cells via apoptosis.  Inhibition of NAD(P)H oxidase and other pro-oxidant 
enzymes has been reported to significantly induce apoptosis of cancer cells [137,138].  Several 
agents have been utilized to test this hypothesis, however, few have been tested in ovarian cancer 
[139-141].  
In this study, we sought to further investigate the role of oxidative stress in the 
pathogenesis of ovarian cancer through the modulation of several key pro-oxidants, iNOS, MPO, 
or NAD(P)H oxidase utilizing siRNA technology and direct inhibition of these enzymes.  
Identification of targets to specifically reduce pro-oxidants and/or induce apoptosis in EOC cells 
may provide a potential therapeutic target for selective elimination of cancer cells. 
Methods 
Cell culture of EOC cell lines, MDAH-2774 and SKOV-3 is described in General 
Methods.  For siRNA experiments, cells (2 X 106) were plated in 60 mm x 15mm cell culture 
dishes.  For inhibition of NAD(P)H oxidase experiments, cells were plated (5 × 106) in 100 cm2 
culture dishes and incubated for 24 hours following treatment with 10 μM DPI (Sigma-Aldrich, 
Saint Louis, MO) for 0, 0.5, 1, 3, 6, 12, and 24 hours.  The dose of DPI was selected based on 
previous studies [139-141]. Cells were harvested at each time point.  All experiments were 
performed in triplicate. Real-time RT-PCR methods are described in General Methods. 
siRNA Design, Synthesis, and Transfection for iNOS and MPO 
SiRNAs were designed after determination of target sequences by aligning iNOS and 
MPO sequences to an Ambion web-based algorithm.  The 21-nucleotide duplex siRNA 
molecules with 3-dTdT overhangs were re-suspended in nuclease-free water according to the 
instructions of the manufacturer (Ambion, Austin, TX).  To ensure stringent controls, both a 2A-
based mutated control siRNA with 2 nucleotide mismatches (siRNA-2Amut) and a scrambled 
control sequence (siRNA-SCR) obtained from Ambion (Silencer Negative Control No. 1 siRNA, 
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Ambion) were used.  
Cells were grown to a confluence of 30% to 40% in 12-well plates (BD Bioscience, 
Franklin Lakes, NJ) and transfected with the use of 3 µL NeoFX reagent (Ambion), 2 μl of 20 
µmol siRNA, and OptiMEM medium (Invitrogen) up to a final volume of 100 μl.  Neo FX 
reagent and siRNA were incubated at room temperature for 10 minutes and then applied onto 1.0 
X 105 cells per well.  Transfection mixtures were incubated with cells for 24 hours before 
washing cells with medium and incubated for an additional 24 hours.  Experiments were 
performed in triplicate for each of the two cell lines.  
Detection of S-nitrosylation of Caspase-3 Following siRNA Knockdown of iNOS or MPO 
Ovarian cancer cell lysates from the different treatments were immunoprecipitated with 
anti-caspase-3 polyclonal antibody conjugated with protein A/G plus agarose beads. 
Immunoprecipitated caspase-3 zymogen was released by boiling the beads at 95 °C for 5 minutes.  
Biotinylated proteins were separated by SDS-PAGE and detected using nitrosylation detection 
reagent I (HRP), according to the manufacturer’s protocol. 
Measurement of Caspase-3 Activity 
Chemicon's Caspase-3 Colorimetric Activity Assay Kit (Chemicon, Temecula, CA) was 
used.  The assay is based on spectrophotometric detection of the chromophore p-nitroaniline 
(pNA) after cleavage from the labeled substrate DEVD-pNA.  The free pNA can be quantified 
using a spectrophotometer or a microtiter plate reader at 405 nm.  Comparison of the absorbance 
of pNA from an apoptotic sample with an uninduced control allows determination of the fold 
increase in caspase-3 activity.  Cells (2 x 106) were harvested and lysed in 300 µl of cell lysis 
buffer included with the kit, and concentrations were equalized for each sample set.  
Subsequently, 150 µg of cell lysate was combined with substrate reaction buffer containing 30 
µg of caspase-3 substrate, acetyl-DEVD-р-nitroaniline (Ac-DEVD-pNA).  This mixture was 
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incubated for 1h at 37°C, and then absorbance was measured with a plate reader (Ultramark, 
BIO-RAD, Hercules, CA).  Background reading from cell buffers and substrate were subtracted 
from the readings of samples before calculating increase in caspase-3 activity. 
Measurement of Apoptosis by TUNEL Assay 
DNA fragmentation was assessed by the in situ Terminal Deoxynucleotidyl Transferase-
mediated dUTP-biotin nick end labeling (TUNEL) technique per the DeadEnd Fluorometric 
TUNEL System (Promega, Madison, WI) manufacturer’s protocol and as we have previously 
described [142,143].  Positive controls were performed by treating cells with DNase I (1 mg/ml) 
in TdT buffer for 10 minutes at room temperature before incubation with a biotinylated 
nucleotide.  Briefly, the cells were fixed with 4% paraformaldehyde in PBS for 20 min at 4 °C, 
and subjected to permeabilization for 5 min at room temperature with 0.2% Triton X-100. Next, 
cells were labeled with the TUNEL reaction mixture for 60 min at 37 °C.  The nuclei of these 
cells were also stained with 4′,6′-diamino-2-phenylindole (DAPI).  Fluorescein-labeled DNA, an 
indication of DNA fragmentation, was analyzed by using an Axiovert immunofluorescent 
microscope (Carl Zeiss Microimaging, Thornwood, NY) and recorded with a microscope-
mounted camera (Carl Zeiss) using DAPI (blue) and FITC (green), fluorescent filters with 
excitation and emission wavelengths of 365 and 445, 470 and 525 nm respectively.  
Measurement of SOD3 Protein Levels in EOC Cells Following Inhibition of NA(P)DH Oxidase 
Immunoprecipitation (IP)/Western blot was utilized as previously described with the 
following changes [144].  Cells were lysed with lysis buffer and cleared by centrifugation (10 
minutes at 1,000g, 4 °C).  Protein concentration of cell lysates was measured with the Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL) per the manufacturer’s protocol.  
The same concentration of protein was utilized for each sample.  Precleared cell lysates were 
incubated with anti-SOD3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour at 
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4 °C, followed by precipitation with 20 μl of Protein A/G PLUS-Agarose (Santa Cruz 
Biotechnology) and incubated at 4 °C overnight.  Adherent proteins were eluted with 1 x protein 
loading buffer for 5 minutes at 80 °C and analyzed by a Western blot detection kit (Visualizer, 
Millipore, Temecula, CA). SOD3 bands were scanned and analyzed by NIH Image J 3.0 (.U. S. 
National Institutes of Health, Bethesda, Maryland). 
Measurement of HIF-1α Levels in EOC Cells Following Inhibition of NA(P)DH Oxidase 
Protein concentration of cell lysates was measured as described in General Methods.  
Cell lysates were prepared from the various treatments of the EOC cell lines, SKOV-3 and 
MDAH-2774.  HIF-1α was measured with an enzyme-linked immunosorbent assay kit (HIF-1α 
ELISA, R&D Systems, Minneapolis, MN), per the manufacturer's protocol.  
Statistical Analysis 
For siRNA studies, data were analyzed using SPSS 15.0 for Windows.  A mixed model 
repeated measures ANOVA was used with treatment as the within factor and cell type as the 
between factor.  Paired comparisons with a Bonferroni correction were used to compare pairs of 
treatments.  Significant interactions between treatment and cell type were analyzed with 
independent sample t-tests by cell type on each treatment.  
For inhibition of NAD(P)H oxidase studies, data were analyzed using SPSS 19.0 for 
Windows.  Additionally, data were analyzed using one-way ANOVA (analysis of variance) with 
Student Neuman-Kuels post-hoc comparisons.  
Results 
Cross-talk between MPO and iNOS gene expression in EOC cells 
To determine the relationship between iNOS and MPO gene expression in EOC cells, we 
utilized the siRNA technology to silence iNOS gene expression and examined MPO expression, 
and vice-versa.  Our results clearly indicate that silencing iNOS gene expression resulted in a 47 
36 
 
and 36% reduction in MPO gene expression in MDAH-2774 and SKOV-3, respectively (Figure 
12A).  Similarly, silencing MPO gene expression also resulted in a 43 and 42% reduction in 
iNOS gene expression in MDAH-2774 and SKOV-3, respectively (Figure 12B).  There was no 
difference in MPO and iNOS mRNA levels between control and scrambled nonspecific siRNA 
(data not shown).  *p<0.05 as compared to control.  Error bars represent standard deviation of 
the mean. 
 
Silencing iNOS and MPO gene expression decreased nitrate/nitrite levels. 
The Griess assay was performed in 24-hour media collected from after silencing iNOS or 
MPO gene expression utilizing specific siRNA (Figure 13).  *p<0.05 as compared to their 
 
Figure 12: Real-time RT-PCR for MPO and iNOS in EOC Cells Following Silencing of 
Either iNOS or MPO. Total RNA isolated from EOC cells, MDAH-2774 and SKOV-3, before 
and after silencing MPO and iNOS gene expression using siRNA specific probes were analyzed 
utilizing real-time RT-PCR. There was no significant difference between controls and 
nonspecific scrambled siRNA (Data not shown). *p<0.05 as compared to control. Experiments 
were performed in triplicate.	
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controls. Error bars represent standard deviation of the mean. 
 
Silencing iNOS and MPO gene expression decreased S-nitrosylation of caspase-3 in EOC cells. 
Since the activity of caspase-3 depends on the level of its S-nitrosylation, we investigated 
the level of S-nitrosylation of caspase-3 in the two cell lines before and after silencing iNOS or 
MPO gene expression utilizing specific siRNA.  The levels of S-nitrosylation of caspase-3 were 
markedly lower in response to silencing either iNOS or MPO, but to a greater extent when 
silencing MPO (Figure 14).  There was no difference in the intensity between control and 
scrambled nonspecific siRNA (data not shown).  *p<0.05 as compared to their control.  Error 
bars represent standard deviation of the mean. 
 
 
 
Figure 13: Nitrate/nitrite levels in EOC Cells Following Silencing of Either iNOS or 
MPO. Levels of nitrate/nitrite were determined in media before and after silencing MPO and 
iNOS gene expression using siRNA specific probes. *p<0.05 as compared to controls. Error 
bars represent standard deviation of the mean.	
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Silencing iNOS or MPO gene expression increased caspase-3 activity and apoptosis in EOC cells. 
We have previously reported that EOC cell lines SKOV-3 and MDAH-2774 manifested a 
marked decrease in their rate of apoptosis and significantly higher rate of proliferation [46,145].  
The cause for lower apoptosis is not yet known.  Caspase-3 activity increased by 161 and 418% 
in SKOV-3 and 156 and 446% in MDAH-2774 when silencing iNOS or MPO gene expression 
utilizing specific siRNA for iNOS or MPO, respectively (Figure 15A).  TUNEL assay showed 
that these treatments were associated with increased apoptosis in both cell lines (Figure 15B).  
*p<0.05 as compared to control.  Error bars represent standard deviation of the mean. 
 
Figure 14. S-Nitrosylation of Caspase-3 in EOC Cells Following Silencing of Either 
iNOS or MPO. S-nitrosylation of caspase-3 in EOC cells, SKOV-3 before (1) and after 
silencing MPO gene expression with specific siRNA (2) and MDAH-2774 before (3) and 
after silencing iNOS gene expression with specific siRNA probes (4). There was no 
significant difference between controls and nonspecific scrambled siRNA (Data not shown). 
Experiments were performed in triplicate. *p<0.05 as compared to control.	
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DPI treated EOC cells had reduced levels of NAD(P)H oxidase mRNA. 
Real-time RT-PCR was utilized to determine the mRNA level of the NAD(P)H oxidase 
p22phox subunit, a representative O2 sensing subunit of NAD(P)H oxidase, in EOC cells treated 
with and without DPI for 0.5 hours.  NAD(P)H oxidase was significantly decreased by 51.6% in 
SKOV-3 cells, and by 40.1% in MDAH-2774 cells (*p<0.05 as compared to control, Figure 16).   
 
Figure 15: Measurement of Apoptosis Following Silencing of Either iNOS or MPO. A) 
Caspase-3 Activity was measured in EOC cells, MDAH-2774 and SKOV-3, before and after 
silencing iNOS or MPO gene expression utilizing siRNA specific probes. A caspase-3 
colorimetric activity assay kit was utilized as described in methods. There was no significant 
difference between controls and nonspecific scrambled siRNA (Data not shown). As can been 
seen from this figure, caspase-3 activity was significantly increased when silencing MPO or 
iNOS. Experiments were performed in triplicate. *p<0.05 as compared to control. B) The 
amount of DNA fragmentation (apoptosis) was assessed by TUNEL assay for EOC cells, 
MDAH-2774 and SKOV-3, before and after silencing iNOS or MPO gene expression 
utilizing siRNA specific probes.  Nuclei were stained with DAPI (blue) and apoptotic cells 
were visualized with fluorescein-12-dUTP (green). There was no significant difference 
between controls and nonspecific scrambled siRNA (Data not shown). Experiments were 
performed in triplicate.	
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DPI treated EOC cells exhibited increased caspase-3 activity and apoptosis.  
Caspase-3 activity significantly increased, in a time dependent fashion, in SKOV-3 cells, 
from 7.62 to 20.9, 20.3, 22.0, 24.5, 39.4, and 54.3 μM and in MDAH-2774 cells from 6.61 to 
19.0, 20.4, 23.1, 25.6, 39.3, and 53.1 μM at the 0.5, 1, 3, 6, 12, and 24 hour time points, 
respectively (*p<0.05 as compared to control, Figure 17A).  
These results were confirmed by TUNEL staining, an indicator of the degree of DNA 
fragmentation, which is representative of apoptosis.  Nuclei were stained with DAPI (blue) and 
apoptotic cells were visualized (60x) with fluorescein-12-dUTP (green).  There was a significant 
increase in TUNEL staining (green) as compared to controls, in both EOC cell lines (Figure 17B).  
 
 
 
Figure 16: Real-time RT-PCR for NAD(P)H oxidase in EOC Cells Following Inhibition 
of NAD(P)H Oxidase. Expression of the NAD(P)H oxidase subunit p22phox mRNA levels in 
SKOV-3 and MDAH-2774 before and after DPI treatment (10 μM, 0.5 hrs) was measured 
using real-time RT-PCR. Results are representative of the mean of three independent 
experiments. (*p<0.05 as compared to their control).	
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DPI treated EOC cells had reduced levels of HIF-1α. 
DPI treatment significantly reduced HIF-1α mRNA levels, in SKOV-3 cells, from 428.2 
to 368.2, 318.6, 268.8, 261.3, and 206.8 pg/μg RNA at the 0.5, 3, 6, 12, and 24 hour time points, 
and in MDAH-2774 cells from 421.3 to 356.9, 356.1, 327.4, 260.3, 240.0 and 223.1 pg/μg RNA, 
at the 0.5, 1, 3, 6, 12, and 24 hour time points, respectively (*p<0.05 as compared to control, 
Figure 18A).  There was no statistically significant change in HIF-1α mRNA levels at the 1 hour 
time point in SKOV-3 cells. 
HIF-1α protein levels, in SKOV-3 cells, were significantly reduced from 1699 to 828.0, 
 
 
Figure 17: (A) Caspase-3 Activity and (B) Apoptosis in EOC Cells Following Inhibition 
of NAD(P)H Oxidase.  (A) Caspase-3 activity was measured in cell lysates from SKOV-3 
and MDAH-2774 before and after DPI treatment (10 μM) at various time points. (B) The 
amount of DNA fragmentation (apoptosis) was assessed by TUNEL assay in MDAH-2774 
and SKOV-3, before and after DPI treatment (10 μM, 12 and 24 hrs) as compared to control 
cells. Nuclei were stained with DAPI (blue) and apoptotic cells were visualized (60x) with 
fluorescein-12-dUTP (green). Results are representative of the mean of three independent 
experiments. (*p<0.05 as compared to their control).	
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377.2, 311.0, 291.1, 224.6, and 44.27 pg/ml total protein and in MDAH-2774 cells from 1872 to 
658.1, 332.4, 257.5, 111.8, 106.1, and 22.96 pg/ml total protein at the 0.5, 1, 3, 6, 12, and 24 
hour time points, respectively (p<0.05 as compared to control, Figure 18B).  
 
DPI treated EOC cells had reduced levels of SOD3  
DPI treatment significantly reduced SOD3 mRNA levels, in a time dependent fashion, 
from 31.1 to 19.5, 24.6, 15.7, 9.23, 4.63, and 3.41 fg/μg RNA at the 0.5, 1, 3, 6, 12, and 24 hour 
 
 
Figure 18: HIF-1α levels in EOC Cells Following Inhibition of NAD(P)H Oxidase.  (A) 
HIF-1α mRNA levels in SKOV-3 and MDAH-2774 before and after DPI treatment (10 μM), 
at various time points, were measured using real-time RT-PCR. (B) ELISA was performed at 
different time points for cell lysates from SKOV-3 and MDAH-2774 before and after DPI 
treatment (10 μM) at various time points. Results are representative of the mean of three 
independent experiments. Results are representative of the mean of three independent 
experiments. (*p<0.05 as compared to their control). 	
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time points, respectively, in SOKV-3 cells (*p<0.05 as compared to control, Figure 19A).  
Similarly, SOD3 mRNA levels were significantly reduced from 26.1 to 19.69, 16.0, 11.7, 8.63, 
and 6.68 fg/μg RNA at the 0.5, 3, 6, 12, and 24 hour time points, respectively, in MDAH-2774 
cells (p<0.05 as compared to control, Figure 19A).  There was no significant change in SOD3 
mRNA levels at the 1 hour time point in MDAH-2774 cells.   
Cell lysates from SKOV-3 and MDAH2774 before and after DPI treatment were 
precipitated with anti-SOD3 antibody and fractionated with SDS-PAGE.  Membrane was probed 
with anti-SOD3 antibody. B: Immunoprecipitation of SOD3 from SKOV-3 (Lane 1-7), and 
MDAH2774 (Lane 8-14), exposed to SOD3. C: IP/Western blot results were scanned and 
analyzed by NIH image J 3.0. SOD3 protein levels, in SOKV-3 cells, were reduced from 251.6 
to 223.2, 215.7, 181.6, and 149.0 at the 3, 6, 12, and 24 hour time points, respectively (*p<0.05 
as compared to control, Figure 19C) and in MDAH-2774 cells from 254.4 to 237.9, 230.4, 208.5, 
188.4, and 170.1 at the 1, 3, 6, 12, and 24 hour time points, respectively (*p<0.05 as compared to 
control, Figure 19C).  There was no significant change in SOD3 protein levels at the 0.5 hour 
time point in both SKOV-3 and MDAH-2774 cells and at the 1 hour time point in SKOV-3 cells. 
Results were expressed as relative levels as compared to their control. 
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Discussion 
Our results clearly show that modulation of pro-oxidant enzymes iNOS, MPO, or 
NAD(P)H oxidase resulted in increased apoptosis as evident by an increase in caspase-3 activity 
and TUNEL staining in EOC cells.  Furthermore, silencing of iNOS or MPO resulted in a 
decrease in nitrate/nitrite, and decrease in S-nitrosylation of caspase-3, suggesting a positive 
regulation of apoptosis through S-nitrosylation of caspase-3.  On the other hand, inhibition of 
NAD(P)H oxidase decreased both SOD and HIF-1α expression in EOC cells, which is indicative 
of a decrease in O2− production. Collectively, these findings further support a role for these key 
enzymes in the pathogenesis of ovarian cancer through regulation of apoptosis and are 
summarized in Figure 20.   
 
 
Figure 19: SOD3 levels in EOC Cells Following Inhibition of NAD(P)H Oxidase.  (A) 
SOD3 mRNA levels in SKOV-3 and MDAH-2774 before and after DPI treatment (10 μM), at 
various time points, were measured using real-time RT-PCR. (B) IP/Western blot was utilized 
to detect SOD3 protein levels in EOC cell lines, SKOV-3 and MDAH-2774 before and after 
DPI treatment.  Lysates were precipitated with anti-SOD3 antibody and fractionated with SDS-
PAGE.  Membrane was probed with anti-SOD3 antibody.  Immunoprecipitation of SOD3 
exposed to SOD3 antibody are as follows: Lanes 1 & 8; control, Lanes 2 & 9; 0.5 hr, Lanes 3 & 
10; 1 hr, Lanes 4 & 11; 3 hr, Lanes 5 & 12; 6 hr, Lanes 6 & 13; 12 hr, and Lanes 7 & 14; 24 hr. 
(C): IP/Western blot results were scanned and analyzed by NIH image J 3.0. Results are 
representative of the mean of three independent experiments. (*p<0.05 as compared to their 
control).	
45 
 
Molecular alterations that lead to apoptosis can be inhibited by S-nitrosylation of 
apoptotic proteins such as caspases.  Thus, S-nitrosylation conveys a key influence of NO on 
apoptosis signaling and may act as a key regulator for apoptosis in cancer cells.  It is known that 
the effects of NO on apoptosis are not only stimulatory but also inhibitory as shown in this study.  
These paradoxical effects of NO on apoptosis seem to be influenced by a number of factors.  It 
has been suggested that biological conditions, such as the redox state, concentration, exposure 
time and the combination with O2, O2− and other molecules, determine the net effects of NO on 
apoptosis [146].  Also, NO is implicated in both apoptotic and necrotic cell death depending on 
the NO chemistry and the cellular biological redox state [146].  We have previously 
demonstrated that the EOC cell lines, SKOV-3 and MDAH-2774, manifest lower apoptosis and 
have significantly higher levels of NO due to the presence of high levels of iNOS [46,145].  
Additionally, it has been shown that MPO can consume NO in the presence of the co-substrate 
H2O2 [49].  Based on these reports we hypothesized that MPO uses the existing cellular NO to 
produce NO+, which is the main source of protein S-nitrosylation, specifically caspase-3 in EOC 
cell lines.  
Since resistance to apoptosis is a hallmark of tumor growth, identifying mechanisms of 
this resistance such as S-nitrosylation may be a key in cancer progression.  S-nitrosylation is 
	
 
Figure 20:  Summary of the effect of modulating oxidative stress in EOC cell lines, 
SKOV-3 and MDAH-2774. Silencing MPO or iNOS, and inhibition of NAD(P)H oxidase 
led to an overall increase in apoptosis in EOC cells.	
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reversible and seemingly specific post-translational modification that regulates the activity of 
several signaling proteins [147].  S-nitrosylation of the catalytic site cysteine in caspases serves 
as an on/off switch regulating caspase activity during apoptosis in endothelial cells, lymphocytes, 
and trophoblasts [129-131].  Several mechanism of denitrosylation have now been demonstrated 
and include activation of the Fas apoptotic pathway or through the thioredoxin or S-
nitrosoglutathione pathways [127,148].  Thus, targeting MPO may be a potential therapeutic 
intervention to reverse the resistance to apoptosis in epithelial ovarian cancer cells. 
In this study we also sought to determine the effects of inhibiting the generation of ROS 
by DPI, a well-characterized, potent inhibitor of flavoenzymes including NAD(P)H oxidase, on 
apoptosis of EOC cells, and whether these effects are associated with SOD3 and HIF-1α 
expression [149,150].  Diphenyleneiodonium has been used to inhibit ROS production mediated 
by NAD(P)H oxidase in various cell types [134,150,151].  We have demonstrated EOC cells to 
have elevated NAD(P)H oxidase, which was subsequently reduced by DPI, a NAD(P)H oxidase 
inhibitor, as indicated by a decrease in the NAD(P)H oxidase p22phox subunit.  These findings are 
supported by the fact that increased NAD(P)H oxidase levels promote the tumorigenic potential 
of NIH3T3 mouse fibroblasts as well as the DU-145 prostate epithelial cells [149].  
Inhibition of NAD(P)H oxidase has been reported to significantly limit the conversion of 
molecular O2 to O2●–, H2O2 and other ROS [137,138].  Growing evidence suggests that cancer 
cells exhibit increased intrinsic ROS stress, due in part to oncogenic stimulation, increased 
metabolic activity, and mitochondrial malfunction [152,153].  Further support for this increase in 
ROS is demonstrated by a cross-talk between mitochondria and the O2●– generating NAD(P)H 
oxidase in ovarian tumors [90].  The mitochondria controls NAD(P)H oxidase redox signaling, 
therefore loss of this control contributes to tumorigenesis [90].  In agreement with a previous 
study, we have shown that inhibition of NAD(P)H oxidase-dependent ROS generation with DPI 
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induced apoptosis in EOC cells, suggesting that the ROS produced by NAD(P)H oxidase, at least 
in part, exert an anti-apoptotic function [154].  This anti-apoptotic mechanism involves induced 
inhibition of phosphorylation of AKT and subsequent suppression of AKT-mediated 
phosphorylation of ASK1 on Ser-83 [154-156].  Furthermore, the anticancer drug paclitaxel-
induced apoptosis of ovarian cancer cells is mediated by negative regulation of AKT–ASK1 
phosphorylation signaling whereas AKT activation by H2O2 confers protection against apoptosis 
[154-156]. 
In addition, we have shown that DPI treatment significantly reduced SOD3 and HIF-1α 
mRNA levels as early as 30 minutes after treatment, with significant further reduction over the 
following 24 hours in EOC cells.  A parallel reduction in protein levels, although not with 
equivalent magnitude, was also observed for both SOD3 and HIF-1α as determined by 
IP/Western blot and ELISA. This may be a consequence of post-translation modifications, which 
may result in increased stability and/or lower degradation of the proteins.  These findings 
demonstrated that inhibition of NAD(P)H oxidase attenuates the expression of both SOD3 and 
HIF-1α, at the mRNA and protein levels.  Moreover, our results showed that the inhibition of 
NAD(P)H oxidase significantly induced apoptosis of EOC cells, as assessed by both caspase-3 
activity and TUNEL assays.  Therefore, there appears to be a strong association between the 
inhibition of NAD(P)H oxidase and the subsequent reduction in SOD3 and HIF-1α levels and 
increase in apoptosis of EOC cells.  
The correlation between HIF-1α and cellular apoptosis has previously been demonstrated 
in lung and hepatoma cancer cells [138,157].  Apoptosis can regulate HIF-1α through the 
modulation of the ratio of pro-apoptotic Bcl-2 and anti-apoptotic Bcl-2 family proteins [158].  
Anti-apoptotic Bcl-2 and Bcl-xL levels have been shown to increased and pro-apoptotic BAX 
and BAK levels were decreased with the over-expression of HIF-1α [158].  Also, it has been 
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reported that inhibition of HIF-1α by rapamycin resulted in an increase in apoptosis of cancer 
cells, and decrease in the expression of apoptosis inhibitor Bcl-2 in ovarian cancer xenografts 
and that rapamycin enhanced cell death through the inhibition of cell survival signals in a 
number of cell lines [159]. Rapamycin has been demonstrated to decrease HIF-1α through 
interference with the mechanism that promotes the stabilization of this protein under hypoxic 
conditions [160]. 
Most of the generated O2●– undergoes a nonenzymatic or SOD-catalyzed reaction, 
generating H2O2 as an end product [161-163].  Hydrogen peroxide is freely diffusible through 
biological membranes, and its overproduction is extremely destructive to cells and tissues, yet it 
is physiologically important among ROS given its relative long half-life in the intracellular space, 
and that it is the precursor of the more toxic hydroxyl radicals [162-164].  It has been reported 
that increased SOD3 expression in ovarian cancer is a cellular response to intrinsic ROS stress 
[70].  However, the role of SOD3 in tumorigenesis is somewhat controversial.  It has been 
recently demonstrated, in mice, that subcutaneous inoculation of the SOD3 gene significantly 
suppressed lung cancer metastasis and that over-expression of SOD3 resulted in in vivo 
inhibition of growth of B16-F1 melanoma tumors [165,166].  In contrast, inhibition of SOD has 
been shown to selectively induce apoptosis of leukemia and ovarian cancer cells, confirming our 
findings from the present study [34]. 
Under hypoxic conditions, high expression levels of SOD3 are reported to significantly 
induce the expression of HIF-1α in tumors, and thus demonstrate a relationship between the 
SOD3 and HIF-1α pathways [159].  The mechanism by which SOD3 upregulates HIF-1α is not 
well understood, but there is substantial evidence to suggest that this mechanism is modulated, in 
part, by the steady-state level of O2●– and the stabilization of HIF-1α [167].  Therefore, reduction 
of O2●– levels via inhibition of NAD(P)H oxidase may result in lowering SOD3 levels, leading to 
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the destabilization of HIF-1α, subsequently increasing apoptosis.  
Collectively, based on previously discussed published reports and the results from this 
study, we conclude that lowering oxidative stress, either through inhibition of iNOS, MPO or 
NAD(P)H oxidase induces apoptosis in ovarian cancer cells and may serve as potential targets 
for future ovarian cancer therapy. 
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CHAPTER V: MYELOPEROXIDASE AND FREE IRON LEVELS: POTENTIAL 
BIOMARKERS FOR EARLY DETECTION AND PROGNOSIS OF OVARIAN 
CANCER 
(This chapter contains previously published material. See Appendix [168]) 
Approach 
Routine screening for ovarian cancer in the general population is not recommended 
because traditional screening methods lack sensitivity and specificity.  We are the first to report 
an increase in MPO expression in epithelial ovarian cancer as compared to normal ovarian 
tissues and cells.  This expression of MPO was surprising, as it is believed to be expressed solely 
in cells of hemopoietic origin.  The elucidation of the function of MPO in EOC is the basis for 
the chapter.  Recently it has been shown in vitro that HOCl, produced from H2O2 by MPO in the 
presence of chloride, can destroy MPO and serve as a source of free iron [169].  This study 
sought to identify whether a relationship exists between serum MPO and free iron with stage of 
ovarian cancer and their potential roles as biomarkers for the early detection of ovarian cancer.  
Both serum and tissue samples were collected from women with stages I through IV ovarian 
cancer, benign gynecologic conditions, inflammation (endometriosis), and healthy controls.  
Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue 
MPO and free iron levels, respectively.  The VITROS Fe Slide Assay was performed in 
collaboration with the Chemistry Department at Wayne State University, Detroit, MI.  
Data were analyzed using SPSS 19.0 for windows (SPSS for Windows, Chicago, IL).  
Data were analyzed using one-way ANOVA (analysis of variance) with Student Neuman-Kuels 
post-hoc comparisons.  P < 0.05 were considered statistically significant for all analyses. 
Introduction 
The underlying pathophysiology of epithelial ovarian cancer is not clearly understood [1].  
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Because early-stage ovarian cancer presents with nonspecific symptoms, diagnosis is often not 
made until after the malignancy has spread beyond the ovaries [170].  The development of 
sensitive and specific methods for early detection has been a priority as a means for improving 
the diagnosis and treatment of this disease. 
The role of MPO, an enzyme stored in the azurophilic granules of polymorphonuclear 
neutrophils and macrophages, and is released into the extracellular fluid in response to 
inflammation in carcinogenesis, has been implicated in both the activation of procarcinogens to 
genotoxic intermediates and the potentiation of xenobiotic carcinogenicity [109,110].  Clinical 
studies have documented the association between inflammation and certain cancers for decades 
[171].  There is convincing evidence that inflammation is a contributing factor in ovarian cancer 
development, but the role of complement-induced inflammation in tumor initiation or 
progression remains poorly investigated [172,173].  Stimulated inflammatory cells are capable of 
inducing genotoxic effects, such as DNA strand breaks, sister chromatid exchanges and 
mutations, and promotion of neoplastic transformation in nearby cells [174].  Myeloperoxidase 
utilizes H2O2, the dismutation product O2●–, to generate HOCl, a cytotoxic and antimicrobicidal 
oxidant.  
We have recently reported that MPO is expressed in EOC cells and tissues with limited 
or no expression in normal ovarian tissues [45].  Studies from our laboratory clearly indicated 
that MPO is responsible for the S-nitrosylation of caspase-3, which inhibited its activity [45].  
Silencing MPO gene expression by the utilization of MPO specific siRNA induced apoptosis in 
EOC cells through a mechanism that decreases MPO-induced S-nitrosylation of caspase-3 [147].  
Additionally, we have compelling evidence that leads us to believe that MPO may serve as a 
source of free iron under oxidative stress, where both NO and O2●– are elevated [175].  Recently 
we have shown that, hypochlorous acid (HOCl), the final product of MPO, displays the potential 
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capacity to mediate hemoprotein heme destruction and subsequent iron release, providing a 
potential link between elevated MPO and free iron [176-178].  
The free iron generated by hemeoprotein destruction not only contributes to elevation of 
serum iron levels, but may also induce oxidative stress, which can promote lipid peroxidation, 
DNA strand breaks, and modification or degradation of biomolecules [179-181].  Iron reacts 
with H2O2 and catalyzes the generation of highly reactive hydroxyl radicals, which in turn 
further increases free iron concentrations by the Fenton and Haber–Weiss reaction [182].  
Several studies from our laboratories have provided a mechanistic link between oxidative stress, 
MPO, higher levels of HOCl and higher free iron that could explain the observed accumulation 
of free iron in epithelial ovarian cancers tissues [45,175-178].  
The search for non-invasive, cost-effective ovarian cancer biomarker tests has been 
ongoing for many years.  Immunizations of mice with ovarian cancer cells has led to hybridoma 
validation by ELISA, while flow cytometry analysis permitted the discovery of cancer antigen 
(CA)-125 and mesothelin [5].  Furthermore, the screening of an array of 21,500 unknown 
ovarian cDNAs hybridized with labeled first-strand cDNA from ten ovarian tumors and six 
normal tissues led to the discovery of human epididymis protein 4 (HE4) [16].  Most 
interestingly, HE4 is overexpressed in 93% of serous and 100% of endometrioid EOCs, and in 
50% of clear cell carcinomas, but not in mucinous ovarian carcinomas [183].  Although it is not 
tissue-specific, a number of independent microarray studies identified HE4 as one of the most 
useful biomarkers for ovarian cancer [13,16,184,185].  In addition to expression on the cellular 
level, secreted HE4 was detected in high levels in the serum of ovarian cancer patients [186].  
Additionally, combining CA-125 and HE4 is a more accurate predictor of malignancy than either 
alone [187-189]. 
In this study, we sought to identify a positive correlation between serum MPO and free 
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iron with stage of ovarian cancer as well as tissue MPO and free iron with stage of ovarian 
cancer and assess their potential roles as biomarkers for the early detection of ovarian cancer. 
Methods 
Patient Population 
A description of the demographics of the study groups are listed in Tables 2 and 3. 
 
 
 
 
 
Table 2.  Descriptive statistics for age including Mean, Median, and Standard deviation, n=30. 
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Ovarian Cancer Cases 
Serum (N=15) and tissues (N=27) were collected from patients presenting to the 
gynecologic oncology division of Karmanos Cancer Institute with suspected EOC were invited 
to participate in a prior study.  They underwent informed consent (Wayne State University 
Human Subject Committee protocol number 027201MP2E) and agreed to provide a blood 
sample prior to treatment (chemotherapy or surgery).  Cases include early through late-stage 
diagnoses as well as a variety of histologies. Stage I is designated as early-stage, as compared to 
remaining stages II through IV (II-IV). 
Table 3.  Comparative study of the cases and control based on cancer status.  
 
Pearson Chi-Square was used for statistical test, p<0.05 was considered statistically significant. There was 
no statistically difference between the two groups based on age and race. However, the region or source 
where the specimen was obtained demonstrated a statistically significant difference that can be attributed to 
the regional and centers characteristics. 
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Benign Controls 
Serum (N=14) and tissues (N=14) from patients with benign gynecologic conditions was 
procured through the Cooperative Human Tissue Network (CHTN).  These include women 
diagnosed with ovarian cysts, endometriosis (inflammation), or uterine fibroids. 
Healthy Controls 
Healthy control sera (n=8) were procured from women recruited through a local 
community organization.  These women presented as healthy, with no history of cancer.  Basic 
information such as age, race, and evidence of benign gynecologic conditions, if any, was 
obtained at the time of informed consent.  The age and racial makeup of this group overlaps with 
patients with ovarian cancer and benign conditions but is not explicitly matched.  
Additionally, we utilized matched tissue samples from the same patient derived serum 
samples to assess the correlation between MPO and iron in these tissues.  In this way we 
assessed if there was an expected discrimination in the tissues and to what extent that 
discrimination diluted in the serum.  
Sample Collection and Processing 
A single 7 cc vial of blood was obtained during normal phlebotomy and the serum was 
isolated after clotting. Serum was collected into a red top or SST blood tube.  The serum clot was 
allowed to form over 1-2 hours and was pelleted in a desktop centrifuge at 2400 rpm for 10 min.  
The serum was removed by pipetting and ~1 ml aliquots were stored at –80 °C.   Samples were 
labeled with a coded identifier.  
Detection of Myeloperoxidase 
Myeloperoxidase was detected with the Myeloperoxidase Enzyme Immunometric Assay 
Kit (Enzo Life Sciences, Farmingdale, NY).  This is a well-established assay in our laboratory 
and was performed according to the manufacturer’s protocol.  This kit is for the quantitative 
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determination of MPO in biological fluids or tissues.  The kit uses a monoclonal antibody to 
MPO immobilized on a microtiter plate to bind the MPO in the standards or sample.  A native 
MPO Standard was provided in the kit.  Rabbit polyclonal antibody to MPO was added and 
binds to the MPO captured on the plate followed by the addition of goat anti-rabbit IgG 
conjugated to horseradish peroxidase, which binds to the polyclonal MPO antibody.  The 
enzyme reaction is stopped generating a red color detected at 450 nm.  The measured optical 
density is directly proportional to the concentration of MPO in either standards or samples.  The 
sensitivity of the assay, defined as the concentration of human MPO was determined to be 0.019 
ng/mL.  All experiments were performed in triplicate. 
Detection of Free Iron 
The VITROS Fe Slide method (VITROS 750, Johnson & Johnson, Rochester, USA) was 
used for detecting serum and tissue iron levels as described by the manufacturer’s protocol.  
Briefly, 10 L of sample is applied to a VITROS Fe DT Slide, which then is loaded into a 
VITROS 950 chemistry system (Ortho Clinical Diagnostics, Inc) located at the University Health 
Building.  The iron in the sample was removed from transferrin at acidic pH and migrates to a 
reducing layer where ascorbic acid reduces it to the ferrous form.  The ferrous iron then is bound 
to a dye, producing color that is detected (600 nm) as a rate of change in reflection density.  
While most females have serum iron levels between 37 and 170 g/dL, this assay has a 
reportable range of 10 to 500 g/dL, and is therefore is suitable for detection in both tissues and 
sera. All experiments were performed in triplicate. 
Statistical Analysis 
Data were analyzed using SPSS 19.0 for windows (SPSS for Windows, Chicago, IL).  
Data were analyzed using one-way ANOVA (analysis of variance) with Student Neuman-Kuels 
post-hoc comparisons. P < 0.05 was considered statistically significant for all analyses. 
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Results 
Ovarian cancer stages II-IV manifested higher levels of tissue MPO. 
All stages of ovarian cancer had significantly higher levels of MPO as compared to 
benign and inflammatory groups (Figure 19, p< 0.05).  Also, ovarian cancer stages II-IV had a 
significantly higher level of MPO as compared to early-stage ovarian cancer (Figure 21, p<0.05).  
The benign group is not significantly different from the inflammatory group.  At the time of 
running this experiment, no healthy control tissue samples were available.  
 
Ovarian cancer stages II-IV manifested higher levels of serum MPO.  
Ovarian cancer stages II-IV had significantly higher levels of MPO as compared to early-
 
 
Figure 21: Tissue MPO: Tissue MPO was detected with the Myeloperoxidase Enzyme 
Immunometric Assay Kit, as described in methods. Early-stage ovarian cancer and ovarian 
cancer stages II-IV are significantly different than all other groups and each other (p< 0.05). 
The benign group is not significantly different from the inflammatory group. At the time of 
running this experiment, no healthy control tissue samples were available. In benign 
gynecologic conditions, the outlier represents a value more than three interquartile ranges 
above the 75th percentile value.	
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stage ovarian cancer, control, benign, and inflammatory groups (p<0.05, Figure 22).  Early-stage 
ovarian cancer and inflammatory gynecologic conditions are significantly different from the 
control and benign groups, while not significantly different from one another (p<0.05, Figure 22).  
Also, control and benign groups were not significantly different. 
 
Ovarian cancer stages II-IV manifested higher levels of tissue iron.  
All stages of ovarian cancer had significantly higher levels of tissue iron than benign and 
inflammatory groups (p<0.05, Figure 23).  In addition, ovarian cancer stages II-IV had higher 
levels of iron as compared to early-stage ovarian cancer (p<0.05, Figure 23).  The benign group 
is not significantly different from the inflammatory group. At the time of running this experiment, 
 
 
Figure 22: Serum MPO: Serum and tissue MPO was detected with the Myeloperoxidase 
Enzyme Immunometric Assay Kit, as described in methods. Ovarian cancer stages II-IV are 
significantly different than all other groups (p<0.05). Early-stage ovarian cancer and 
inflammatory gynecologic conditions are different from control and benign groups, while 
not one another (p<0.05). Control and benign groups are not statistically different. In stages 
II-IV, the outlier represents a value more than three interquartile ranges above the 75th 
percentile value.	
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no healthy control tissue samples were available. 
 
Ovarian cancer stages II-IV manifested higher levels of serum iron. 
All stages of ovarian cancer had significantly higher levels of serum iron as compared to 
control, benign, and inflammatory groups (p< 0.05, Figure 24).  In addition, ovarian cancer 
stages II-IV had higher serum iron levels as compared to early-stage ovarian cancer (p< 0.05, 
Figure 24).  There are no significant differences between control, benign and inflammatory 
groups. 
 
Figure 23: Tissue iron: Serum and tissue iron were detected using the VITROS Fe Slide 
method as described in methods. Ovarian cancer stages II-IV and early-stage ovarian cancer 
are significantly different than all other groups as well as each other (p<0.05). The benign 
group is not significantly different from the inflammatory group. At the time of running this 
experiment, no healthy control tissue samples were available. In inflammatory gynecologic 
conditions and stages II-IV, the outliers represent a value more than three interquartile 
ranges above the 75th percentile value.	
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Discussion 
The findings from this study, indicate a role for the combination of serum MPO and free 
iron as biomarkers for early detection and prognosis of ovarian cancer.  Multi-marker panels 
have the potential for high positive predictive values (PPVs), but careful validation with 
appropriate sample cohorts is mandatory and complex algorithms may be difficult to implement 
for routine clinical use [5].  Panels of biomarkers have been extensively investigated to improve 
sensitivity and specificity and have included some of the most promising reported markers such 
as CA72-4, M-CSF, OVX1, LPA, Prostacin, Osteopontin, Inhibin and Kallikrein [190-192].  
While these and other potential screening paradigms with comparable sensitivities and 
 
Figure 24: Serum iron: Serum and tissue iron were detected using the VITROS Fe Slide 
method as described in methods. Ovarian cancer stages II-IV and early-stage ovarian cancer 
are significantly different than other groups as well as each other (p<0.05). There are no 
significant differences among the control, benign and inflammatory groups. In stage I, the 
outlier represents a value more than three interquartile ranges above the 75th percentile 
value.	
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specificities have been previously reported, these assays often require specialized equipment not 
routinely utilized in the clinical immunoassay laboratory, or rely on complex computational 
algorithms to generate adequate assay performance [193].  With an ovarian cancer prevalence of 
only 1 in 2500 among postmenopausal women in the U.S., an effective screening strategy for the 
general population needs to attain a sensitivity of 75% and specificity about 99.6% to attain a 
minimally acceptable potential PPV of 10% for the detection of all stages of ovarian cancer 
[193].  No single biomarker reported to date has met these thresholds. 
The observation of the involvement of MPO in oxidative stress and inflammation has 
been a leading factor in the study of MPO as a possible marker of plaque instability and a useful 
clinical tool in the evaluation of patients with coronary heart disease [194]. Recent genetic 
studies implicated MPO in the development of lung cancer by demonstrating a striking 
correlation between the relative risk for development of the disease and the incidence of 
functionally distinct MPO polymorphisms [195]. 
We now have substantial evidence to believe that the presence of MPO may play a role in 
maintaining the oncogenic phenotype of EOC cells [45].  In support of this notion, 
polymorphisms at position –463 (G to A) in the promoter region of the MPO gene have been 
identified, with the A variant allele related to decreased transcriptional activity and decreased 
MPO expression, which may be associated with reduced risk of human cancers [196].  
Myeloperoxidase requires heme as a cofactor, which consists of an iron atom contained in the 
center of a large heterocyclic organic ring [197].  Thus, the MPO G allele might produce more 
ROS when iron intake is high.  Previous studies have investigated the combined roles of MPO 
and iron levels on cancer development, as well as assessed the impact of MPO genetic 
polymorphisms on the development of cirrhosis with hereditary hemochromatosis [41,198].  
They found that the MPO GG genotype was more common in patients with cirrhosis than in 
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those without, modifying the clinical penetrance of hepatic iron overload with respect to hepatic 
fibrosis in hereditary hemochromatosis.  
Myeloperoxidase levels reported for various inflammatory disorders are coincidentally 
lower than those levels found in all stages of ovarian cancer.  A previous study reported normal 
serum MPO and iron levels as 62 ± 11 ng/ml and 96 ± 9 g/dl, respectively [199]. However, 
there was a significant increase in serum MPO and iron levels to 95 ± 20 ng/ml, and 159 ± 20 
g/dl, respectively, in asthmatic individuals [199].  Although there was an increase in this 
reported serum iron, these levels still fell within the normal range (50 to 170 μg/dl) [200,201].  
Other studies have showed that an elevated MPO level, reaching up to 350 ng/ml, in serum 
plasma, was indicative of a higher risk for cardiovascular events in patients hospitalized for chest 
pain [202,203].  Our data showed an overlap between serum MPO levels in early-stage ovarian 
cancer with inflammation.  However, serum iron levels were significantly higher in early-stage 
ovarian cancer as compared to inflammation.  Thus, there is a potential for a false positive with 
MPO alone in patients with cardiovascular, inflammation, and/or asthmatic disorders. 
Utilizing serum iron levels alone as a biomarker is also not sufficient for early detection 
of ovarian cancer due to many uncontrolled variables, i.e. dietary intake, supplements, effects of 
other iron-generating enzymes or factors, and more importantly they are not as specific as MPO 
levels.  Specifically, in iron deficiency anemic patients, their free iron levels may become a 
confounding factor in its utilization for early detection of ovarian cancer.  Thus, anemia should 
be ruled out to eliminate any overlap that would lead to misdiagnosis.  The incorporation of iron 
deficiency anemic patients in a logistic regression model will help determine its overlap with 
early-stage ovarian cancer.  Additionally, currently available clinical studies focused on either 
biochemical or more recently, genetic markers of iron overload have reported conflicting results 
regarding the use of iron levels alone for diagnosis [204-207].  For these reasons, we expect that 
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the combination of serum MPO and iron levels to yield a higher power of specificity and 
sensitivity that should distinguish women with early-stage ovarian cancer from other disorders, 
specifically inflammation.  Additionally, combining serum MPO and iron levels with the best 
currently existing biomarkers through the creation of a logistic regression model may increase 
the overall predictive values.  Collectively, our data strongly supports a role for serum MPO and 
free iron in the pathophysiology of ovarian cancer, which thereby qualifies them to serve as 
biomarkers for early detection and prognosis of ovarian cancer.  
To validate MPO and free iron as biomarkers for early detection of ovarian cancer, we 
are currently planning a follow up study on a larger population with the principal endpoint of 
establishing the best cutoff point using the receiver operating characteristic (ROC) method [208-
210].  Also, we will generate sensitivity, specificity, and positive and negative predictive values 
for serum MPO and free iron alone and in combination.  These results will be compared to the 
existing CA-125 biomarker.  As a secondary endpoint, we plan to performed survival analysis 
using the Kaplan-Meier method with MPO and free serum levels as factors. 
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CHAPTER VI: A NAD(P)H OXIDASE SINGLE NUCLEOTIDE POLYMORPHISM IS 
ASSOCIATED WITH AN INCREASED RISK OF OVARIAN CANCER 
Approach 
In Chapter III, we observed an increase in NAD(P)H oxidase expression in ovarian 
cancer as compared to normal ovarian tissues, which serves as the rationale for this chapter.  
Additionally, in Chapter IV, we observed that inhibition of NAD(P)H oxidase lead to an increase 
in apoptosis in EOC cells, thus indicating a role for this enzyme in the pathogenesis of ovarian 
cancer, and serves as the rationale for this chapter.  Single nucleotide polymorphisms are 
associated with increased risk of several cancers.  We evaluated the association of a SNP 
(rs4673) in the CYBA gene, encoding the p22phox subunit of NAD(P)H oxidase, substituting 
allele C with T at position 242 located on chromosome 16q24, in high-risk individuals with or 
without ovarian cancer, with or without a deleterious BRCA1/2 mutation.  This NAD(P)H 
oxidase subunit serves as an oxygen detector and confers the activity of the enzyme.  
To achieve this study, 139 individuals were recruited, in collaboration with the Karmanos 
Cancer Institute, Detroit, MI, based on personal and family history of cancer.  Blood samples 
were collected and underwent DNA extraction followed by TaqMan® SNP Genotype analysis 
for rs4673 utilizing the QuantStudio 12K Flex Real-Time PCR System in collaboration with the 
Applied Genomics Technology Center (AGTC, Wayne State University, Detroit, MI).  Data 
were analyzed using SPSS (IBM, Armonk, New York) for Mac V.21.  Pearson Chi-square 
analyses were performed 1) to compare the SNP mutation frequencies in the present sample to 
that in the general population; 2) to examine the associations among BRCA1/2 status, SNP status, 
and cancer status.  Binary logistic regression analyses were performed to study the response of 
SNP status to the changes in age at enrollment, race, BRCA1/2 status, and cancer status; using 
the likelihood ratio forward stepwise methods.   
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Introduction 
While the chances of long-term patient survival are significantly increased when ovarian 
cancer is detected at its early stage, to date, there is no reliable method available for early 
detection of ovarian cancer [2].  In fact, the absence of definitive symptoms causes the survival 
following diagnosis and treatment of ovarian cancer to fall from a 90% 5-year survival rate in 
cases when detected at its early stage, to less the than 30% chance when the disease is detected at 
a late stage [2,211,212]. 
Epidemiologic studies have clearly established the role of family history as an important 
risk factor for both breast and ovarian cancers [213].  It is well established that germline 
mutations in BRCA1 or BRCA2 result in a predisposition to ovarian cancer, however at a rate of 
only 20-40%, suggesting the presence of other, unidentified mutations in other predisposition 
genes [214-217].  Additional genetic variations including SNPs, many of which have been 
identified in recent genome-wide association studies (GWAS), have been hypothesized to act as 
low to moderate penetrant alleles which contribute to breast and ovarian cancer risk, as well as 
other diseases, [216,218,219].  Single-nucleotide polymorphisms arise because of point 
mutations that are selectively maintained in populations that are distributed throughout the 
human genome at an estimated overall frequency of at least one in every 1000 base pair [220].  
Non-synonymous SNPs substitute encoded amino acids in proteins, and are more likely to alter 
the structure, function, and interaction of the protein [216,221].  Therefore SNPs are good 
candidates as disease-modifiers and have been associated with an altered cancer risk. 
It has been reported that mutations in specific regions of NAD(P)H oxidase subunits 
contribute to the enhancement of the enzyme activity with subsequent increase in O2●− 
production, contributing to enhanced levels of oxidative stress [79,80].  Specifically, an increase 
in NAD(P)H oxidase activity has been associated with a specific SNP in the CYBA gene (rs4673), 
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encoding the p22phox subunit of NAPDH oxidase, resulting in a CAC/TAC replacement at 
position 242 located on chromosome 16q24, leading to a nonconservative substitution of 
histidine-72 with a tyrosine [81].  This SNP is also associated with an increased risk for other 
diseases where oxidative stress plays a critical role in their pathophysiology, including 
cardiovascular disease, asthma, and diabetic nephropathy [81-83].  
Oxidative stress has been implicated in the pathogenesis of several malignancies, 
including ovarian cancer [20,47].  Specifically, we have recently demonstrated an increased 
expression of pro-oxidant enzymes such as iNOS, MPO, NAD(P)H oxidase, as well as an 
increase in NO as indicated by increased nitrate/nitrite in EOC tissues and cells [46,47].  In this 
study, we report that the NAD(P)H oxidase 242C>T SNP is significantly associated with not 
only ovarian cancer patients, but also with high-risk individuals.  A combination analysis of this 
SNP with the currently used BRCA1/2 mutation risk factor resulted in an even stronger 
association.  These findings suggest a possible future role of this SNP as a biomarker to identify 
those at an increased risk for development of ovarian cancer.    
Methods 
Patient Population 
A total of 139 individuals were recruited through the Karmanos Cancer Institute’s 
Genetic Registry (KCIGR), Detroit, MI.  Participants in the genetics registry were recruited 
through the Karmanos Cancer Institute’s cancer genetic counseling service and included 
individuals determined to be eligible for BRCA1 and BRCA2 germline testing based on their 
personal and family history of cancer and were identified as having ovarian cancer or were 
“high-risk” based on this family history [211]. Research activities were conducted with the 
approval of Wayne State University Institutional Review Board.  DNA samples were utilized to 
determine the frequency of the polymorphism in the CYBA gene that results in a CAC/TAC 
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replacement (rs4673). High-risk non-cancer and ovarian cancer samples used for this study were 
collected from participants recruited between 1999 and 2012.  At the time of enrollment in the 
genetics registry, individual and family cancer history was obtained including history of ovarian 
cancer and other cancers [211].  Genetic testing for BRCA1/2 was conducted by Myriad Genetics 
Laboratories (Salt Lake City, Utah) [211].  Individuals with unknown BRCA1/2 mutation status 
were excluded from of BRCA1/2 analysis.  A description of the patient demographics is in Table 2. 
Purification of DNA for SNP Sequencing 
DNA, from blood samples, was isolated by the Applied Genomics Technology Center 
(AGTC, Detroit, MI). DNA was extracted with QIAamp DNA mini kit (Qiagen) [211]. 
TaqMan SNP Genotyping Assay for p22phox 242 C>T 
The TaqMan® SNP Genotyping Assay Set (Applied Biosystems, Carlsbad, CA) for 
rs4673 (NCBI dbSNP genome build 37, MAF source 1000 genomes) was used to genotype the 
242C>T SNP in the CYBA gene, which encodes the p22phox subunit of NAD(P)H oxidase, 
located on chromosome 16q24.  The AGTC also performed this assay.  Analysis was done 
utilizing the QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems). 
Statistical Analysis 
Data were analyzed using SPSS (IBM, Armonk, New York) for Mac V.21. Pearson Chi-
square analyses were performed 1) to compare the SNP mutation frequencies in the present 
sample to that in the general population; 2) to examine the associations among BRCA1/2 status, 
SNP status, and cancer status.  Binary logistic regression analyses were performed to study the 
response of SNP status to the changes in age at enrollment, race, BRCA1/2 status, and cancer 
status; using the likelihood ratio forward stepwise methods.   
Results 
The study population included 139 women with an age range of 18-90, and a median age 
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of 50 years. The racial distribution of the population included 92.8% White, 5.0% Black, and 
2.2% other/unknown.  Of the participants in the study, 35.3% had a diagnosis of ovarian cancer.  
The genotype frequency for the NAD(P)H oxidase SNP in individuals with ovarian cancer was 
as follows: CC= 30.6%, CT= 49.0%, and TT=20.4% (Figure 23).  The frequency for the SNP 
(CT + TT) was 69.4% as compared to a minor allele frequency (MAF) of 30.3% reported for the 
general population (NCBI) (Figure 23, Chi Squared= 74.8, p<0.0001).  Genotype frequency for 
the NAD(P)H oxidase SNP in individuals who were high-risk non-cancer was as follows: CC= 
38.9%, CT= 42.2%, and TT=18.9% (Figure 25).  The frequency for the SNP (CT + TT) was 
61.1% as compared to 30.3% in the general population, although not quite significant (NCBI) 
(Figure 25, Chi Squared=3.1, p<0.08). There was a slight increase in the frequency of the minor 
allele in individuals with ovarian cancer (69.4%) as compared to high-risk non-cancer and 
control individuals (61.0%) (Figure 25, p>0.05 with d=21%).  
 
 
 
Figure 25: Frequency of NAD(P)H oxidase SNP in EOC. Frequency of the alleles at 
position 242 of the CYBA gene located on chromosome 16q24 present in the general 
population, controls, high-risk non-cancerous individuals and individuals with ovarian cancer. 
This SNP (rs4673, NCBI dbSNP genome build 37, MAF source 1000 genomes) in the CYBA 
gene, encoding the p22phox subunit of NAD(P)H oxidase, results in a CAC/TAC replacement.  
69 
 
BRCA1/2 status was available for 92.1% of the individuals (n=116) of which 11.2% with 
ovarian cancer were BRCA1/2 positive as compared to 17.2% of the high-risk non-cancer 
individuals.  For individuals with BRCA1/2 mutations, there was an increase in the minor allele 
frequency in individuals with ovarian cancer as compared to high-risk non-cancer individuals 
(69.2 vs. 45.0%; p>0.05 with d=26%); for individuals without BRCA1/2 mutations, there was 
also a small increase (71.0 vs. 65.4%; p>0.05 with d=7%).   
Logistic regression analyses revealed that age at enrollment was a significant predictor of 
SNP status (p=0.027).  With a one year increase in age at enrollment, the odds of an individual 
developing a mutated SNP increase by 3.4% after controlling for race, BRCA1/2 status, and 
cancer status.  
Discussion 
In this study we have shown that the NAD(P)H oxidase 242C<T SNP was not only 
significantly associated with patients with ovarian cancer, but also with those individuals who 
are considered high-risk.  Patients utilized for this study were at an elevated risk of harboring a 
BRCA1/2 mutation based on personal and family history of cancer [211].  During the study 
period, 31.2% patients presented with or developed the disease.  Our results clearly show 69.4% 
of those with ovarian cancer have the CT or TT alleles as compared to a MAF of 30.3% in the 
general population, indicating a strong association of this SNP with ovarian cancer.  Yet, 61.1% 
of high-risk non-cancer individuals also have the CT or TT alleles, further suggesting the 
association of this SNP with an increased risk of development of ovarian cancer, which is again 
significantly higher than the reported 30.3% MAF in the general population (NCBI). 
Although there are several SNPs reported for the NAD(P)H oxidase enzyme, the current 
study focused on the 242C>T SNP in the CYBA gene (which encodes the p22phox subunit of 
NAD(P)H oxidase) located on chromosome 16q24 because of the previously reported 
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association between this SNP and several other diseases such as hypertension, cerebrovascular 
disease, diabetes and nephropathy as well as being associated with reduced respiratory burst in 
isolated human neutrophils [81,222-224].  This SNP has been evaluated in a limited number of 
cancers including lung cancer and leukemia and was found not to be associated with an increased 
risk [225,226].  The A-930G polymorphism (rs9932581) located in the promoter region is 
associated with higher promoter activity, hypertension, as well as an increase in exposure to 
oxidative stress [81,227,228].  The A640G polymorphism (rs1049255) is a silent variant located 
in the 3' untranslated region of CYBA and has been suggested to be associated with 
cardiovascular arterial disease [81,228-230].  Future studies examining the prevalence of the 
above mentioned SNPs is worthwhile conducting as the results of this study suggest a role for 
NAD(P)H oxidase in the pathogenesis of ovarian cancer.   
It is well understood that the breast cancer susceptibility genes, BRCA1 and BRCA2, are 
also strongly associated with an increased risk of ovarian cancer [231].  Of the individuals in our 
study who have ovarian cancer and the BRCA1/2 mutation (10%), 69.2% had the CT or TT 
alleles as compared to 48.0% of high-risk non-cancer individuals, which was not statistically 
significant.  Low statistical power due to small sample size in the present study may have limited 
the significance of some of the statistical comparisons.  While the total sample size (n=139 
overall and n=130 for BRCA1/2 status) might appear sufficient, the cell size for individual Chi-
square tests were small.  For example, for individuals with BRCA1/2 mutations, the sample size 
for normal and mutated SNP groups were 17 and 21, respectively, resulting in a low power of 
26%.  A sample size of 62 and 75, respectively, would be needed to achieve statistical power at 
the recommended 80% level [232].   
It is known that NAD(P)H oxidase regulates several redox intracellular signaling 
pathways through the generation of ROS molecules. NAD(P)H oxidase utilizes NAD(P)H as an 
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electron donor to generate O2●– from molecular oxygen. NAD(P)H oxidase consists of seven 
isoforms: five NOXs, NOXs1–5, and two NOX homologues, DUOX1 and DUOX2 [233]. NOX 
enzymes are differentially activated by different binding molecules, including p22phox, p40phox, 
p47phox /NOXO1, p67phox /NOXA1 and Rac [77].  NOX enzymes are essential for the control of 
many cell functions including, differentiation, proliferation, and cell death, as well as signal 
transduction [234].  The generation of ROS molecules, specifically O2●–, is achieved by 
activation of certain redox-sensitive transcription factors, inhibition of protein tyrosine 
phosphatases, and modulation of the functions of some ion channels [71,235].  NAD(P)H 
oxidase/ROS-mediated signaling might therefore serve as an alert signal, which stimulates the 
cells either to adapt to the stress or to undergo apoptosis [235].  Indeed we have previously 
shown that inhibition of NAD(P)H oxidase significantly induced apoptosis in EOC cells [47].  
Additionally, inhibition of NAD(P)H oxidase not only resulted in a reduction of its own 
expression, but also a significantly decreased SOD3 and HIF-1α levels in EOC cells [47].  Thus, 
a polymorphism favoring a pro-oxidant intercellular milieu may prove beneficial to the 
persistence of the cancer cell, and targeting NAD(P)H oxidase may serve as a strategy for 
increasing apoptosis. 
Growing bodies of evidence from clinical studies support the concept that increases in 
NAD(P)H oxidase activity plays a central role in the etiology of various diseases [79,90,236].  
Recent studies have demonstrated that NOX4 is expressed in several tumor types, including 
ovarian cancer [237].  NAD(P)H oxidases can be activated by mechanical forces, hormones, and 
cytokines [79,238].  More importantly, NAD(P)H gene polymorphisms have the ability to 
stimulate the activity of NAD(P)H oxidases, as well as increase the expression of its subunits 
[79,238,239].  Specifically, NOX2 is considered to be directly involved in the generation of O2●–, 
as well as p22phox, p47phox and p67phox [71].  Other studies have shown that polymorphisms in the 
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promoter region of the p22phox gene contribute to the upregulation of p22phox in spontaneously 
hypertensive animals [79,80].  Indeed, treatment of animals with antioxidants or inhibitors of 
NAD(P)H oxidase results in significantly lower ROS levels, and is associated with decreased 
blood pressure [239,240]. 
Recent GWAS have successfully identified and confirmed six SNPs that appear to 
influence the risk of EOC [212].  The confirmed susceptibility SNPs are rs3814113 (located at 
9p22, near BNC2), rs2072590 (located at 2q31, which contains a family of HOX genes), 
rs2665390 (located at 3q25, intronic to TIPARP), rs10088218 (located at 8q24, 700 kb 
downstream of MYC), rs8170 (located at 19p13, near MERIT40), and rs9303542 (located at 
17q21, intronic to SKAP1) [212].  In this study we report another SNP that is strongly associated 
with ovarian cancer, rs4673. This SNP is particularly important because the resulting pro-oxidant 
milieu is significant in the pathophysiology of several diseases, including ovarian cancer.  
The findings of this study are of great importance because they can be utilized as a 
stepping-stone towards the development of an early screening test for identifying individuals 
who are at high-risk for the development of ovarian cancer.  
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CHAPTER VII: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
The overall goal of these studies was to investigate the role of oxidative stress in EOC 
and understand the underlying mechanisms of oxidative stress in this disease.  To achieve this 
goal, we have successfully shown that EOC favors a pro-oxidant state, which is responsible for 
the maintenance of the oncogenotype.  We have identified key players in the redox pathway in 
EOC whose modulation results in increased apoptosis in EOC cells.  Additionally, we have 
identified MPO and free iron as biomarkers for the early detection of ovarian cancer. 
Furthermore, we have shown that a SNP in NAD(P)H oxidase serves as a screening tool for the 
identification of individuals at high risk for ovarian cancer. 
Collectively, this work provides the molecular basis for future clinical trials testing the 
potential for MPO and free iron as biomarkers for early detection of ovarian cancer.  Similar 
studies are needed for the evaluation of NAD(P)H oxidase as a screening tool for the general 
population.  Due to the low prevalence of ovarian cancer in U.S. women, an ovarian cancer 
diagnostic or screening test must have a minimum specificity of 99.6% before it can be used 
routinely in the general population of postmenopausal women [170,241].  Such a test may offset 
potential morbidity and mortality, which can be associated with complications of surgery for 
patients who have false-positive ovarian cancer screening tests [170,241].  An ovarian cancer 
screening test should also have high sensitivity and a suitable PPV [170,242].  Routine screening 
for ovarian cancer in the general population is not recommended because traditional screening 
methods are not sensitive or specific enough [170,243].  Therefore, the development of sensitive 
and specific methods for early detection has been a priority as a means for improving the 
diagnosis and treatment of this disease.  Additional studies focusing on modulation of the key 
enzymes identified in this study are needed to assess their potential as therapeutic targets. 
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ABSTRACT 
THE ROLE OF OXIDATIVE STRESS IN THE PATHOGENESIS OF EPITHELIAL 
OVARIAN CANCER 
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Ovarian cancer is the leading cause of death from gynecologic malignancies yet the 
underlying pathophysiology is not clearly established.  The disease is usually diagnosed in the 
advanced stage and carries a poor prognosis.  The 5-year survival rate is greater than 75% if 
diagnosis of the cancer occurs at an early stage; however, this rate drops to 20% when the tumor 
has spread beyond its origin.  Thus, a method for early detection is critically needed, which can 
help prolong, or even save lives.  Currently, an effective screening test for ovarian cancer is 
lacking.  Many tests have been evaluated but have been found to be lacking in sensitivity, 
specificity, or both.  This becomes even more difficult as ovarian cancer is so rare in the general 
population, with an estimated prevalence of 0.04%.  To date, 96% is the highest sensitivity 
recorded for the early detection of ovarian cancer.  However, because of the low prevalence of 
ovarian cancer, a sensitivity and specificity of 96% would only detect 1 case of cancer per 100 
oophorectomies done for positive screens due to the high false positive rate.  
Clinical and epidemiological investigations have provided evidence supporting the role of 
reactive oxygen species (ROS) in the prognosis and metastasis of cancer due to exogenous 
factors that lead to chronic inflammation.  In addition, cancer cells are frequently under 
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persistent oxidative stress, which participates in cancer progression as well as in the selection of 
resistant cells that are unable to be eliminated by apoptosis.  A recent novel finding from our 
laboratory has shown that myeloperoxidase (MPO) is expressed in ovarian cancer cell lines and 
tissues, with minimal or no expression detected in normal ovarian tissues.  Myeloperoxidase is 
an abundant heme protein, which plays a central role in the formation of reactive oxidant and 
free radical species.  Additionally, under conditions of oxidative stress, MPO serves as a source 
of free iron.  
Another source of ROS is the superoxide producing nicotinamide adenine dinucleotide 
phosphate (NAD(P)H) oxidase, which we observed to be upregulated in ovarian cancer as 
compared to normal ovarian tissues.  It has been reported that mutations in specific regions of 
NAD(P)H oxidase subunits contribute to the enhancement of the enzyme activity with 
subsequent increase in superoxide (O2●−) production, contributing to enhanced levels of 
oxidative stress. 
Therefore, there is compelling evidence to support the role of oxidative stress in the 
pathogenesis of ovarian cancer, yet the mechanisms responsible for the dissemination of EOC 
are not fully understood.  The objective of this work is to identify mechanisms of oxidative stress 
in the pathogenesis of ovarian cancer.  The central hypothesis of this study is that ovarian cancer 
is controlled by mechanisms that emanate from an altered redox balance.  To test this hypothesis, 
the following specific aims have been investigated: 
 Specific Aim I: Determine the oxidative stress profile in epithelial ovarian cancer and 
determine the effect of the modulation of specific key players of oxidative stress on the 
persistence of the oncogenic phenotype.  To determine the oxidative stress profile, the 
expression of the following markers will be evaluated: NAD(P)H oxidase, nitrate/nitrite, 
glutathione, glutathione reductase, glutathione peroxidase, glutathione s-transferase, inducible 
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nitric oxide synthase, myeloperoxidase, catalase, and superoxide dismutase in epithelial ovarian 
cancer cells and tissues as compared to their normal counterparts.  These markers were selected 
based on extensive preliminary and published results, utilizing a cell culture model and ovarian 
cancer tissues. Modulation of key players of oxidative stress will contribute to delineation of the 
mechanisms of development of ovarian cancer.  To achieve this, a combination of knockdown or 
inhibition of specific pro-oxidants utilizing siRNA or direct inhibition will be performed 
followed by the assessment of the expression other pro-oxidants as well as the effect on 
apoptosis.  
Specific Aim II: To assess the effectiveness of MPO and free iron levels in detection of early 
stage ovarian cancer.  The mechanism by which MPO functions under oxidative stress is not 
well defined. MPO has been indicated to serve as a source of free iron under oxidative stress.  
The hypothesis of this aim is that serum MPO and free iron levels can be utilized to distinguish 
patients with stage I ovarian cancer from those with normal ovaries or benign gynecologic 
conditions as well as from late state ovarian cancer. MPO and free iron levels will be measured 
in the sera and tissues of women at the time of ovarian cancer diagnosis as compared to healthy 
women or those with benign gynecologic disorders respectively.  The biological significance of 
the relationship between serum MPO and free iron, in conjunction with the poor prognosis of 
ovarian cancer has the potential for future clinical applications. .  
Specific Aim III: To assess whether a SNP in NAD(P)H oxidase is associated with increased 
risk of development of ovarian cancer.  Single nucleotide polymorphisms (SNPs) are 
associated with increased risk of several cancers.  We evaluated the association of a SNP 
(rs4673) in the CYBA gene, encoding the p22phox subunit of NAD(P)H oxidase, substituting 
allele C with T at position 242 located on chromosome 16q24, in high-risk individuals with or 
without ovarian cancer, with or without a deleterious BRCA1/2 mutation.  This SNP is known to 
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be associated an increased activity of the enzyme, resulting in an increase in superoxide 
production.  TaqMan® SNP Genotype analysis and the QuantStudio 12K Flex Real-Time PCR 
System were utilized to determine the frequency of this SNP in individuals with ovarian cancer 
as compared to noncancerous individuals. 
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